Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

DOI: 10.1056/nejmoa1215637
New England Journal of Medicine, 2013, 369, 32-42.

#	Paper	IF	Citations
1879	B cell receptor signaling in chronic lymphocytic leukemia. **2013**, 34, 592-601		207
1878	Targeting inflammatory pathways in chronic lymphocytic leukemia. **2013**, 88, 655-66		22
1877	Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. *New England Journal of Medicine*, **2013**, 369, 507-16	59.2	1139
1876	Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas. **2013**, 163, 436-43		61
1875	The emerging role of ibrutinib in the treatment of chronic lymphocytic leukemia. **2013**, 6, 543-6		2
1874	Molecular bases of chronic lymphocytic leukemia in light of new treatments. **2013**, 155, 51-5		10
1873	Antigens in lymphoma development--current knowledge and future directions. **2013**, 23, 397-8		5
1872	Drug discovery: Pocket of opportunity. **2013**, 503, 475-6		14
1871	How I treat patients with relapsed chronic lymphocytic leukaemia. **2013**, 163, 423-35		4
1870	Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. **2013**, 2013, 138-50		24
1869	Ibrutinib and novel BTK inhibitors in clinical development. **2013**, 6, 59		166
1868	A mechanism-driven treatment for chronic lymphocytic leukemia?. *New England Journal of Medicine*, **2013**, 369, 85-7	59.2	16
1867	Ibrutinib in relapsed chronic lymphocytic leukemia. *New England Journal of Medicine*, **2013**, 369, 1278-9	59.2	98
1866	Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. **2013**, 122, 3723-34		87
1865	Targeted therapies in oncology come of age. **2013**, 35, 1256-7		
1864	B-cell receptor signaling as a driver of lymphoma development and evolution. **2013**, 23, 410-21		142
1863	Zielgerichtete Therapien bei h□matologischen Erkrankungen. **2013**, 19, 835-847		

1862	Treatment of older patients with chronic lymphocytic leukemia: key questions and current answers. **2013**, 2013, 158-67	47
1861	Transplantation for mantle cell lymphoma: is it the right thing to do?. **2013**, 2013, 568-74	11
1860	Accelerating safe drug development: an ideal approach to approval. **2013**, 2013, 24-9	3
1859	Molecular pathways: targeting MALT1 paracaspase activity in lymphoma. **2013**, 19, 6662-8	22
1858	The role of chemotherapy in managing chronic lymphocytic leukemia: optimizing combinations with targeted therapy. **2013**, 13, 1089-108	
1857	Ibrutinib for the treatment of chronic lymphocytic leukemia. **2013**, 1, 925-933	2
1856	PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1. **2013**, 110, 21124-9	146
1855	Targeting the Bcl-2 family in B-cell chronic lymphocytic leukemia. **2013**, 2, 397-407	1
1854	Two targets for the price of one. **2013**, 122, 2529-31	7
1853	Maintenance in CLL. **2013**, 122, 3854-5	9
1852	Chronic lymphoid leukemia. **2013**, 19, 409-415	
1851	Stromal control of chronic lymphocytic leukemia cells. **2013**, 23	
1850	Multidimensional single-cell analysis of BCR signaling reveals proximal activation defect as a hallmark of chronic lymphocytic leukemia B cells. **2014**, 9, e79987	8
1849	Endothelin-1 promotes survival and chemoresistance in chronic lymphocytic leukemia B cells through ETA receptor. **2014**, 9, e98818	28
1848	Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. **2014**, 124, 4867-76	132
1847	Ibrutinib: a new frontier in the treatment of chronic lymphocytic leukemia by Bruton's tyrosine kinase inhibition. **2013**, 11, 265-71	8
1846	Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab. **2015**, 8, 1-7	3
1845	Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML. **2014**, 5, 9930-8	51

1844	Mutations responsables de la r^ sistance ^ l[]brutinib dans la LLC. **2014**, 20, 197-198	
1843	PharmaForum. **2014**, 37, 790-791	
1842	Novel treatments for chronic lymphocytic leukemia and moving forward. **2014**, e317-25	17
1841	Nucleic Acids as Molecular Diagnostics in Hematopoietic Malignancies []mplications in Diagnosis, Prognosis, and Therapeutic Management. **2014**, 185-200	
1840	AACR Cancer Progress Report 2014. **2014**, 20, S1-S112	41
1839	4-Amino-2-arylamino-6-(2,6-dichlorophenyl)-pyrido[2,3-d]pyrimidin-7-(8H)-ones as BCR kinase inhibitors for B lymphoid malignancies. **2014**, 86, 664-75	17
1838	Genetic and molecular targets in lymphoma: implications for prognosis and treatment. **2014**, 10, 2509-28	3
1837	Personalized Cancer Therapy. **2014**, 671-824	1
1836	Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art. **2014**, 7, 841-57	12
1835	Bortezomib for the treatment of non-Hodgkin's lymphoma. **2014**, 15, 2443-59	28
1834	[Chronic lymphocytic leukemia: current standards and novel approaches]. **2014**, 55, 1400, 1402-4, 1406-9	
1833	Translational hematology. **2014**, 164, 487-96	
1832	Rho and Rap guanosine triphosphatase signaling in B cells and chronic lymphocytic leukemia. **2014**, 55, 1993-2001	5
1831	Role of allogeneic transplantation in patients with chronic lymphocytic leukemia in the era of novel therapies: a review. **2014**, 5, 139-52	8
1830	Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase. **2014**, 10, 957-67	92
1829	Ofatumumab and high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia. **2014**, 4, e258	10
1828	Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells. **2014**, 28, 1158-63	44
1827	Kinase Inhibitors in Cancer. **2014**,	2

1826	Interference with pre-B-cell receptor signaling offers a therapeutic option for TCF3-rearranged childhood acute lymphoblastic leukemia. **2014**, 4, e181		14
1825	Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma. **2014**, 28, 407-10		33
1824	Ibrutinib: a paradigm shift in management of CLL. **2014**, 7, 705-17		12
1823	Prognostic factors in chronic lymphocytic leukemia: a conceptual approach. **2014**, 3, 145-152		1
1822	Movement toward optimization of CLL therapy. *New England Journal of Medicine*, **2014**, 370, 1160-2	59.2	10
1821	Sodium and potassium regulate endothelial phospholipase C- and Bmx. **2014**, 307, F58-63		4
1820	The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison. **2014**, 25, 200-6		25
1819	The non-receptor tyrosine kinase Tec controls assembly and activity of the noncanonical caspase-8 inflammasome. **2014**, 10, e1004525		37
1818	BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma. **2014**, 2014, 125-34		26
1817	The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy. **2014**, 99, 1138-48		68
1816	Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion. **2014**, 28, 230-3		43
1815	Drug monographs: ibrutinib and ramucirumab. **2014**, 49, 702-9		1
1814	Infection in chronic lymphocytic leukemia: parsimony has its limits. **2014**, 55, 2683-4		
1813	Interaction between myelomonocytic and lymphoid cells in a patient with acute myelomonocytic leukemia and chronic lymphocytic leukemia. **2014**, 55, 1425-7		1
1812	Expression of PIM1 protein in chronic lymphocytic leukemia/small lymphocytic lymphoma. **2014**, 55, 2658-9		2
1811	To the end of chronic lymphocytic leukemia: what should be the role of allogeneic transplant?. **2014**, 55, 1221-2		
1810	Recent advances in the pathogenesis and treatment of chronic lymphocytic leukemia. **2014**, 35, 105-20		0
1809	Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia. **2014**, 99, 881-7		25

1808	Highlights in the treatment of chronic lymphocytic leukemia from the 2013 meeting of the American Society of Hematology. **2014**, 7, 187-90	2
1807	Pharmacogenetics in the treatment of chronic lymphocytic leukemia: what does the future hold?. **2014**, 15, 897-900	1
1806	Chimeric antigen receptor T-cell therapy for ALL. **2014**, 2014, 559-64	40
1805	Recognition of antigen-specific B-cell receptors from chronic lymphocytic leukemia patients by synthetic antigen surrogates. **2014**, 21, 1670-9	19
1804	Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells. **2014**, 89, 757-65	28
1803	New strategies in chronic lymphocytic leukemia: shifting treatment paradigms. **2014**, 20, 5869-74	43
1802	Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies. **2014**, 166, 336-51	36
1801	Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation. **2014**, 89, E239-43	55
1800	CLL/SLL diagnosed in an adolescent. **2014**, 61, 1107-10	3
1799	An old and simple solution for a new problem--more on clinical staging and evaluation of response in B-cell chronic lymphocytic leukaemia in the era of new therapies. **2014**, 165, 737-40	2
1798	Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies?. **2014**, 28, 1055-71	1
1797	Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis. **2014**, 164, 146-50	17
1796	The promising impact of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the management of lymphoid malignancies. **2014**, 34, 303-14	14
1795	Development and characterization of a physiologically relevant model of lymphocyte migration in chronic lymphocytic leukemia. **2014**, 123, 3607-17	21
1794	[Major advances in Oncology in 2013: the editorial board of the Bulletin du Cancer point of view]. **2014**, 101, 75-92	0
1793	Ibrutinib versus Ofatumumab bei vorbehandelter CLL. **2014**, 17, 26-28	1
1792	The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer. **2014**, 351, 538-48	47
1791	Potential therapeutic role of antagomiR17 for the treatment of chronic lymphocytic leukemia. **2014**, 7, 79	11

1790	Modeling the clinical phenotype of BTK inhibition in the mature murine immune system. **2014**, 193, 185-97	18
1789	Targeting the B-cell receptor signaling pathway in B lymphoid malignancies. **2014**, 21, 341-9	26
1788	Do mantle cell lymphomas have an 'Achilles heel'?. **2014**, 21, 350-7	13
1787	Management of chronic lymphocytic leukemia. **2014**, 99, 965-72	28
1786	Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia. **2014**, 10, 1147-55	6
1785	Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib. **2014**, 5, 121-33	44
1784	Harnessing the fc□receptor for potent and selective cytotoxic therapy of chronic lymphocytic leukemia. **2014**, 74, 7510-7520	11
1783	Role of ibrutinib for the treatment of mantle cell lymphoma in the elderly. **2014**, 3, 53-61	
1782	Does B cell receptor signaling in chronic lymphocytic leukaemia cells differ from that in other B cell types?. **2014**, 2014, 208928	6
1781	Ibrutinib-naˆ ve chronic lymphocytic leukemia lacks Bruton tyrosine kinase mutations associated with treatment resistance. **2014**, 124, 3831-3	22
1780	Genetic stratification in myeloid diseases: from risk assessment to clinical decision support tool. **2014**, 5, e0025	
1779	B cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292. **2014**, 3, 29-38	6
1778	Emerging new anticancer biological therapies in 2013 (haematological malignancies). **2014**, 26, 363-70	5
1777	Bruton's tyrosine kinase inhibitors: lessons learned from bench-to-bedside (first) studies. **2014**, 26, 463-8	7
1776	The B-cell receptor pathway: a critical component of healthy and malignant immune biology. **2014**, 51, 206-18	21
1775	Incorporating targeted agents into future therapy of chronic lymphocytic leukemia. **2014**, 51, 235-48	5
1774	The microenvironment in lymphomas--dissecting the complex crosstalk between tumor cells and 'by-stander' cells. **2014**, 24, 1-2	13
1773	New horizons in the treatment of chronic lymphocytic leukemia. **2014**, 45, 122-131	6

1772	Personalized medicine in CLL: current status and future perspectives. **2014**, 352, 4-14		21
1771	The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. **2014**, 24, 71-81		203
1770	Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. **2014**, 123, 2139-47		247
1769	Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. *New England Journal of Medicine*, **2014**, 370, 997-1007	59.2	1303
1768	Imbruvica--next big drug in B-cell cancer--approved by FDA. **2014**, 32, 113-5		8
1767	Ibrutinib: first global approval. **2014**, 74, 263-71		79
1766	Reprint of: A review of cellular therapies for chronic lymphocytic leukemia. **2014**, 20, S18-S21		
1765	Ibrutinib for B cell malignancies. **2014**, 3, 4		56
1764	Targeting Bruton's tyrosine kinase in B cell malignancies. **2014**, 14, 219-32		314
1763	How we treat Richter syndrome. **2014**, 123, 1647-57		116
1762	Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110□for relapsed/refractory chronic lymphocytic leukemia. **2014**, 123, 3390-7		487
1761	High-dimensional single-cell cancer biology. **2014**, 377, 1-21		36
1760	In search of magic bullets: the golden age of immunotherapeutics. **2014**, 157, 227-40		32
1759	Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells. **2014**, 123, 3780-9		16
1758	Warm autoimmune hemolytic anemia: advances in pathophysiology and treatment. **2014**, 43, e97-e104		13
1757	Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. **2014**, 124, 49-62		202
1756	Small Molecules in Oncology. **2014**,		3
1755	Immunomodulation and immune reconstitution in chronic lymphocytic leukemia. **2014**, 51, 228-34		35

1754	Breaking good: the inexorable rise of BTK inhibitors in the treatment of chronic lymphocytic leukaemia. **2014**, 166, 12-22	13
1753	Haematological cancer: Richter's transformation in CLL-a distinct lymphoma. **2014**, 11, 6-8	2
1752	PI3-kinase inhibitors in chronic lymphocytic leukemia. **2014**, 9, 33-43	21
1751	Bruton's tyrosine kinase (BTK) inhibitors in clinical trials. **2014**, 9, 44-9	80
1750	PI3K and cancer: lessons, challenges and opportunities. **2014**, 13, 140-56	1127
1749	Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia--focus on the B-cell receptor. **2014**, 20, 548-56	66
1748	Stereotyped B-cell receptors in chronic lymphocytic leukemia. **2014**, 55, 2252-61	19
1747	Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors. **2014**, 28, 507-17	20
1746	Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis. **2014**, 49, 485-91	10
1745	BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. **2014**, 28, 649-57	140
1744	The orally available Btk inhibitor ibrutinib (PCI-32765) protects against osteoclast-mediated bone loss. **2014**, 60, 8-15	45
1743	A new era of treatment for chronic lymphocytic leukaemia?. **2014**, 15, 3-5	2
1742	Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. **2014**, 15, 48-58	372
1741	B-cell receptor stereotypy and chronic lymphocytic leukaemia. **2014**, 1, e52-3	
1740	Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study. **2014**, 1, e74-84	76
1739	Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups. **2014**, 3, 555-64	17
1738	Ibrutinib, obinutuzumab, idelalisib, and beyond: review of novel and evolving therapies for chronic lymphocytic leukemia. **2014**, 34, 1298-316	10
1737	Prognostic information and biological insights in chronic lymphocytic leukemia by high-resolution immunophenotypic analysis of ZAP70. **2014**, 85, 798-808	3

1736	Ibrutinib resistance in chronic lymphocytic leukemia. *New England Journal of Medicine*, **2014**, 370, 2352-4	59.2	207
1735	Chaetoglobosin A preferentially induces apoptosis in chronic lymphocytic leukemia cells by targeting the cytoskeleton. **2014**, 28, 1289-98		50
1734	Haematological cancer: idelalisib-targeting PI3K□in patients with B-cell malignancies. **2014**, 11, 184-6		37
1733	Combining drugs and biologics to treat nasopharyngeal cancer. **2014**, 22, 8-9		5
1732	Decade in review-haematological cancer: advances in biology and therapy. **2014**, 11, 628-30		2
1731	Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. *New England Journal of Medicine*, **2014**, 371, 213-23	59.2	1154
1730	Obinutuzumab for B-cell malignancies. **2014**, 14, 1197-205		5
1729	Design of reversible, cysteine-targeted Michael acceptors guided by kinetic and computational analysis. **2014**, 136, 12624-30		154
1728	B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies. **2014**, 99, 222-31		43
1727	Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center. **2014**, 28, 1365-8		18
1726	Chemical biology approaches to target validation in cancer. **2014**, 17, 87-100		30
1725	Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells. **2014**, 106,		74
1724	Molecular genetic characterization of terreic acid pathway in Aspergillus terreus. **2014**, 16, 5250-3		23
1723	Ibrutinib: better combined with other drugs?. **2014**, 15, 1043-4		4
1722	Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. **2014**, 15, 1019-26		215
1721	Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. **2014**, 15, 1090-9		283
1720	Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. **2014**, 4, 1022-35		203
1719	A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53. **2014**, 167, 149-61		22

1718	Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group. **2014**, 38, 1269-77		10
1717	Immunogenetic studies of chronic lymphocytic leukemia: revelations and speculations about ontogeny and clinical evolution. **2014**, 74, 4211-6		36
1716	Changes in the treatment landscape for chronic lymphoid leukemia. *New England Journal of Medicine*, **2014**, 371, 273-4	59.2	12
1715	B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies. **2014**, 28, 1163-7		41
1714	Precision therapy for lymphoma--current state and future directions. **2014**, 11, 585-96		55
1713	Neue Entwicklungen in der Therapie maligner hˆ □matologischer Erkrankungen. **2014**, 29, 316-323		
1712	Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL). **2014**, 111, 13906-11		72
1711	A review of cellular therapies for chronic lymphocytic leukemia. **2014**, 20, 164-7		3
1710	Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. *New England Journal of Medicine*, **2014**, 370, 2286-94	59.2	800
1709	Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma. **2014**, 9, 1086-91		55
1708	Management of mantle cell leukemia with cardiac involvement leading to cardiogenic shock. **2014**, 8, 254-8		
1707	Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer. **2014**, 34, 1722-32		53
1706	Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL. **2014**, 123, 3255-62		31
1705	Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician. **2014**, 32, 3039-47		96
1704	New treatment options for chronic lymphocytic leukemia. **2014**, 15, 823-32		6
1703	Rekomendacje diagnostyczne i terapeutyczne dla przewlek□j bia□czki limfocytowej w 2014 r. □ raport Grupy Roboczej PTHiT oraz PALG □CLL. **2014**, 45, 221-239		3
1702	Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies. **2014**, 144, 338-48		43
1701	Targeted cancer therapy: from bench to bedside to patient. **2014**, 32, 268-70		4

1700	Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study. **2014**, 38, 34-41	23
1699	The meaning and relevance of B-cell receptor structure and function in chronic lymphocytic leukemia. **2014**, 51, 158-67	30
1698	Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia. **2014**, 38, 1165-72	10
1697	Ibrutinib and indolent B-cell lymphomas. **2014**, 14, 253-60	11
1696	Lymphoma development in patients with autoimmune and inflammatory disorders--what are the driving forces?. **2014**, 24, 61-70	109
1695	Allogeneic transplantation for lymphoma: risk-benefit balance is in the eye of the beholder. **2014**, 20, 905-6	
1694	Bendamustine in the treatment of chronic lymphocytic leukemia. **2014**, 2, 617-623	2
1693	Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies. **2014**, 32, 1830-9	80
1692	Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. **2014**, 28, 2188-96	125
1691	Bruton's TK inhibitors: structural insights and evolution of clinical candidates. **2014**, 6, 675-95	10
1690	Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. **2014**, 32, 129-60	65
1689	Colocalization of BCL2-positive and -negative follicular lymphoma. **2014**, 28, 1368-70	
1688	Richter's syndrome update on biology and management. **2014**, 2, 453-463	4
1687	Murine genetically engineered and human xenograft models of chronic lymphocytic leukemia. **2014**, 51, 188-205	15
1686	Outcomes of human leukocyte antigen-matched sibling donor hematopoietic cell transplantation in chronic lymphocytic leukemia: myeloablative versus reduced-intensity conditioning regimens. **2014**, 20, 1390-8	14
1685	.	
1684	Shifting ecologies of malignant and nonmalignant cells following BRAF inhibition. **2014**, 124, 4681-3	0
1683	Signal-dependent and signal-independent functions of the B-cell receptor in chronic lymphocytic leukemia. **2014**, 99, 1645-6	

1682	Chronic lymphocytic leukemia: state of the art and beyond. **2014**, 12, 801-3	
1681	Targeting antiapoptotic and proapoptotic proteins for novel´ chronic lymphocytic leukemia therapeutics. **2014**, 3, 233-241	1
1680	PKC-as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL. **2014**, 124, 1481-91	38
1679	Understanding life and death decisions in human leukaemias. **2014**, 42, 747-51	
1678	Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib. **2014**, 123, 4132-5	70
1677	Ibrutinib-associated tumor lysis syndrome in a patient with chronic lymphocytic leukemia. **2014**, 124, 3503-5	19
1676	How will B-cell-receptor-targeted therapies change future CLL therapy?. **2014**, 123, 1455-60	47
1675	Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. **2014**, 123, 1810-7	218
1674	Boldly Targeting Kinases without mutations. **2014**, 123, 1119-21	6
1673	Otlertuzumab more than a TRU(E) toddler in CLL?. **2014**, 123, 1282-4	2
1672	Lymphocytosis and ibrutinib treatment of CLL. **2014**, 123, 1772-4	18
1671	Ibrutinib inhibits BCR and NF-B signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. **2014**, 123, 3286-95	167
1670	Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia. **2014**, 124, 42-8	50
1669	CLLonal selection: survival of the fittest?. **2014**, 123, 2130-1	0
1668	Ibrutinib: targeting the hidden CLL. **2014**, 123, 3215-6	1
1667	CLL cells under flow. **2014**, 123, 3533-4	3
1666	Blood collection methods affect cellular protein integrity: implications for clinical trial biomarkers and ZAP-70 in CLL. **2014**, 124, 1192-5	5
1665	Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK. **2014**, 124, 3101-9	30

1664	A new prognostic score for CLL. **2014**, 124, 1-2	27
1663	Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. **2014**, 124, 3991-5	218
1662	Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab). **2014**, 124, 3059-64	71
1661	Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?. **2014**, 124, 3841-9	158
1660	IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells. **2014**, 124, 3583-6	79
1659	Stress equips CLL cells to survive. **2014**, 124, 3040-1	
1658	Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. **2014**, 124, 3829-30	235
1657	New meets old: a case study and review of novel therapeutics for the treatment of CLL in older patients. **2014**, 12, 1371-5	3
1656	Ask the Experts: Precision medicines: a new era for the treatment of B-cell malignancies. **2014**, 3, 113-116	
1655	Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model. **2014**, 99, 1599-604	44
1654	Use of signaling pathways as therapeutic targets for blood cancer. **2014**, 3, 275-288	
1653	Chronische lymphatische Leuk^ hie beim alten Patienten. **2015**, 21, 486-495	
1652	Prognostic markers and standard management of chronic lymphocytic leukemia. **2015**, 2015, 368-77	24
1651	Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. **2015**, 100, 1571-8	113
1650	Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia. **2015**, 90, 179	13
1649	Ibrutinib and rituximab induced rapid response in refractory Richter syndrome. **2015**, 3, 615-7	11
1648	Targets for Ibrutinib Beyond B Cell Malignancies. **2015**, 82, 208-17	66
1647	VIII. Treatment of chronic lymphocytic leukaemia, where are we heading?. **2015**, 33 Suppl 1, 46-9	3

1646	Generation of a poor prognostic chronic lymphocytic leukemia-like disease model: PKC subversion induces up-regulation of PKCI expression in B lymphocytes. **2015**, 100, 499-510	6
1645	Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. **2015**, 100, e302-6	76
1644	Ibrutinib (Imbruvica): The First-in-Class Btk Inhibitor for Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia. **2015**, 157-166	
1643	Ibrutinib: another weapon in our arsenal against lympho-proliferative disorders. **2015**, 16, 2715-8	3
1642	Chronic Lymphocytic Leukemia. **2015**, 130-144	1
1641	An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. **2015**, 125, 2336-43	127
1640	Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. **2015**, 125, 2062-7	255
1639	Initial treatment of CLL: integrating biology and functional status. **2015**, 126, 463-70	57
1638	FLT3-ITD and TLR9 use Bruton tyrosine kinase to activate distinct transcriptional programs mediating AML cell survival and proliferation. **2015**, 125, 1936-47	41
1637	Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic leukemia. **2015**, 125, 407-10	18
1636	Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma. **2015**, 125, 2079-86	54
1635	A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma. **2015**, 125, 242-8	103
1634	The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. **2015**, 125, 2915-22	92
1633	Future distribution of multiple myeloma in the United States by sex, age, and race/ethnicity. **2015**, 125, 410-2	30
1632	The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the E´ μ-TCL1 mouse model. **2015**, 125, 4032-41	28
1631	The efficacy of ibrutinib in the treatment of Richter syndrome. **2015**, 125, 1676-8	57
1630	Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling. **2015**, 125, 3297-305	107
1629	Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy. **2015**, 125, 2306-9	67

1628	Response: Additional data needed for a better understanding of the potential relationship between atrial fibrillation and ibrutinib. **2015**, 125, 1673	16
1627	Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia. **2015**, 126, 445-53	103
1626	Life after ibrutinib? A new unmet need in CLL. **2015**, 125, 2013-4	5
1625	Targeted therapies in CLL: mechanisms of resistance and strategies for management. **2015**, 126, 471-7	96
1624	A drive through cellular therapy for CLL in 2015: allogeneic cell transplantation and CARs. **2015**, 126, 478-85	33
1623	Three years of ibrutinib in CLL. **2015**, 125, 2455-6	5
1622	Targeted drugs in concert with chemo: opposites attract. **2015**, 125, 2878-9	
1621	Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. **2015**, 126, 2213-9	158
1620	Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL. **2015**, 126, 2110-7	75
1619	Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse. **2015**, 126, 1695-8	99
1618	Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. **2015**, 126, 1921-4	167
1617	Ibrutinib in CLL: 2 sides of the same coin. **2015**, 126, 2173-4	2
1616	Targeting Bruton's tyrosine kinase signaling as an emerging therapeutic agent of B-cell malignancies. **2015**, 10, 3339-3344	8
1615	Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. **2015**, 13, 326-62	37
1614	The microenvironment in chronic lymphocytic leukemia: biology and therapeutic translation. **2015**, 56-71	
1613	Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. **2015**, 121, 3612-21	185
1612	The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia. **2015**, 100, 1495-507	69
1611	Management of elderly patients with chronic lymphocytic leukemia in the era of targeted therapies. **2015**, 27, 365-70	3

1610	CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. **2015**, 171, 726-35	40
1609	Management of Chronic Lymphocytic Leukemia in the Elderly. **2015**, 22, 17-23	16
1608	Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors. **2015**, 10, 55-68	22
1607	Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms. **2015**, 10, 15-23	2
1606	Platinum and high-dose cytarabine-based regimens are efficient in ultra high/high-risk chronic lymphocytic leukemia and Richter's syndrome: results of a French retrospective multicenter study. **2015**, 95, 160-7	17
1605	Loss of B-cell receptor expression defines a subset of diffuse large B-cell lymphoma characterized by silent BCR/PI3K/AKT signaling and a germinal center phenotype displaying low-risk clinicopathologic features. **2015**, 39, 902-11	12
1604	Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes. **2015**, 121, 2883-91	47
1603	Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients. **2015**, 170, 40-9	12
1602	Low-dose alemtuzumab in refractory/relapsed chronic lymphocytic leukemia: Genetic profile and long-term outcome from a single center experience. **2015**, 90, 970-4	2
1601	Tyrphostin AG126 exerts neuroprotection in CNS inflammation by a dual mechanism. **2015**, 63, 1083-99	15
1600	Myeloid Cells as Targets for Therapy in Solid Tumors. **2015**, 21, 343-50	26
1599	The expanding role of bendamustine in chronic lymphocytic leukemia. **2015**, 65	
1598	Targetting BTK/PI-3K□n CLL. **2015**, 21, 117-126	
1597	PI3K and AKT: Unfaithful Partners in Cancer. **2015**, 16, 21138-52	163
1596	Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy. **2015**, 8, 607-36	13
1595	The Role of CD44 in the Pathophysiology of Chronic Lymphocytic Leukemia. **2015**, 6, 177	14
1594	Lymphoma Immunotherapy: Current Status. **2015**, 6, 448	32
1593	A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia. **2015**, 11, 979-90	21

1592	Current concepts in diagnosis and treatment of chronic lymphocytic leukemia. **2015**, 19, 361-7	7
1591	Plant virus particles carrying tumour antigen activate TLR7 and Induce high levels of protective antibody. **2015**, 10, e0118096	51
1590	Global Cell Proteome Profiling, Phospho-signaling and Quantitative Proteomics for Identification of New Biomarkers in Acute Myeloid Leukemia Patients. **2016**, 17, 52-70	20
1589	New insights into malignant B-cell disorders. **2015**, 2015, 128084	
1588	The Changing Therapeutic Landscape of Chronic Lymphocytic Leukemia. **2015**, 05,	
1587	. **2015**,	2
1586	Management of chronic lymphocytic leukemia. **2015**, 164-75	20
1585	Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?. **2015**, 6, 40496-506	35
1584	Targeting CD20 in chronic lymphocytic leukemia. **2015**, 43	
1583	A CD21 low phenotype, with no evidence of autoantibodies to complement proteins, is consistent with a poor prognosis in CLL. **2015**, 6, 32669-80	3
1582	Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma. **2015**, 6, 15122-36	18
1581	New Insights in Prognosis and Therapy of Chronic Lymphocytic Leukaemia. **2015**,	
1580	Prolonged and tunable residence time using reversible covalent kinase inhibitors. **2015**, 11, 525-31	250
1579	Rethinking clinical response and outcome assessment in a biologic age. **2015**, 17, 27	2
1578	The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. **2015**, 126, 328-35	73
1577	Optimized Near-IR Fluorescent Agents for in Vivo Imaging of Btk Expression. **2015**, 26, 1513-8	40
1576	Miliary tuberculosis after initiation of ibrutinib in chronic lymphocytic leukemia. **2015**, 94, 1419-20	15
1575	Potential impact of the hypomethylating agent 5-azacitidine on chronic lymphocytic leukemia with del(17)(p)/del(p53) and subsequent therapy-related acute myeloid leukemia without these aberrations: a case report. **2015**, 8, 144-147	1

1574	Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib. **2015**, 8, 60	43
1573	How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?. **2015**, 56, 587-93	13
1572	Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997. **2015**, 56, 3031-7	7
1571	Novel therapeutic options for relapsed hairy cell leukemia. **2015**, 56, 2264-72	13
1570	Personalized Therapy of Cancer. **2015**, 199-381	1
1569	Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694. **2015**, 290, 5960-78	29
1568	US FDA oncology drug approvals in 2014. **2015**, 11, 1931-45	5
1567	Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective. **2015**, 6, 161-70	12
1566	Ofatumumab in the treatment of non-Hodgkin's lymphomas. **2015**, 15, 1085-91	8
1565	Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies. **2015**, 1358, 82-94	26
1564	Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. **2015**, 28, 690-714	828
1563	High-dose therapy and autologous hematopoietic cell transplantation as front-line consolidation in chronic lymphocytic leukemia: a systematic review. **2015**, 50, 1069-74	5
1562	Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. **2015**, 14, 207	107
1561	Ibrutinib in chronic lymphocytic leukemia. **2015**, 4, 143-150	
1560	ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development. **2015**, 8, 129	164
1559	Mutacje TP53 w nowotworach hematologicznych. **2015**, 46, 327-338	
1558	Modeling absolute lymphocyte counts after treatment of chronic lymphocytic leukemia with ibrutinib. **2015**, 94, 249-56	8
1557	Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. **2015**, 16, 169-76	289

1556	Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. **2015**, 4, e985940	38
1555	New therapies in non-Hodgkin lymphoma. **2015**, 15, 349-59	5
1554	Absorption, metabolism, and excretion of oral ´ □□ radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. **2015**, 43, 289-97	85
1553	Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors. **2015**, 21, 2115-26	51
1552	Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma. **2015**, 56, 2834-40	10
1551	[Major advances in oncology in 2014: the editorial board of the Bulletin du Cancer point of view]. **2015**, 102, 92-104	0
1550	25 years of small molecular weight kinase inhibitors: potentials and limitations. **2015**, 87, 766-75	102
1549	Human organic cation transporter 1 (hOCT1) as a mediator of bendamustine uptake and cytotoxicity in chronic lymphocytic leukemia (CLL) cells. **2015**, 15, 363-71	15
1548	Ten things you should know about protein kinases: IUPHAR Review 14. **2015**, 172, 2675-700	180
1547	Targeted therapy for chronic lymphocytic leukemia: current status and future directions. **2015**, 75, 143-55	4
1546	Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma. **2015**, 75, 594-604	57
1545	The tumor microenvironment shapes hallmarks of mature B-cell malignancies. **2015**, 34, 4673-82	66
1544	Multi-Targeted Approach to Treatment of Cancer. **2015**,	0
1543	Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. **2015**, 100, 77-86	115
1542	Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia. **2015**, 170, 125-8	10
1541	Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies. **2015**, 75, 111-21	44
1540	Ibrutinib inhibits BTK-driven NF-B p65 activity to overcome bortezomib-resistance in multiple myeloma. **2015**, 14, 2367-75	36
1539	Basal Ca(2+) signaling is particularly increased in mutated chronic lymphocytic leukemia. **2015**, 29, 321-8	13

1538 Effect of kinase inhibitors on the therapeutic properties of monoclonal antibodies. **2015**, 7, 192-8 19

1537 Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. **2015**, 27, 409-25 81

1536 Clinical update: B-cell receptor kinase inhibitors in chronic lymphocytic leukemia. **2015**, 8, 38-42 0

1535 Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study. **2015**, 90, 417-21 17

1534 New oral small molecules in the treatment of chronic lymphocytic leukemia. **2015**, 121, 1917-26 2

1533 Advances in the treatment of follicular lymphoma. **2015**, 3, 207-218

1532 Preclinical activity of anti-CCR7 immunotherapy in patients with high-risk chronic lymphocytic leukemia. **2015**, 64, 665-76 13

1531 The pre-BCR to the rescue: therapeutic targeting of pre-B cell ALL. **2015**, 27, 321-3 1

1530 Novel Therapies for Chronic Lymphocytic Leukemia: A Canadian Perspective. **2015**, 15, 627-634.e5 6

1529 Ibrutinib: from bench side to clinical implications. **2015**, 32, 225 8

1528 Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion. **2015**, 6, 242-52 18

1527 Identifying kinase dependency in cancer cells by integrating high-throughput drug screening and kinase inhibition data. **2015**, 31, 3799-806 8

1526 Development and pharmacological validation of novel methods of B cell activation in rat whole blood. **2015**, 71, 61-7

1525 [Ibrutinib: A new drug of B-cell malignancies]. **2015**, 102, S85-90 2

1524 Ibrutinib for the treatment of Waldenstr ̂ Ĥn macroglobulinemia. **2015**, 8, 569-79 12

1523 Targeting neddylation effectively antagonizes nuclear factor-Ƀ in chronic lymphocytic leukemia B-cells. **2015**, 56, 1566-9 6

1522 Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. **2015**, 1, 80-7 398

1521 Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target. **2015**, 56, 3250-6 21

1520	Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. **2015**, 21, 922-6	707
1519	Ibrutinib in B lymphoid malignancies. **2015**, 16, 1879-87	24
1518	Non-coding recurrent mutations in chronic lymphocytic leukaemia. **2015**, 526, 519-24	565
1517	Emerging immunological drugs for chronic lymphocytic leukemia. **2015**, 20, 423-47	9
1516	B-cell receptor signaling in the pathogenesis of lymphoid malignancies. **2015**, 55, 255-65	21
1515	Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse. **2015**, 50, 1279-85	29
1514	Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3K inhibition. **2015**, 29, 744-7	19
1513	CD47 agonist peptides induce programmed cell death in refractory chronic lymphocytic leukemia B cells via PLC activation: evidence from mice and humans. **2015**, 12, e1001796	39
1512	Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia. **2015**, 39, 495-500	41
1511	Strategies targeting apoptosis proteins to improve therapy of chronic lymphocytic leukemia. **2015**, 29, 345-50	7
1510	Activity of Bruton's tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: a mechanistic study using patient-derived blast cells. **2015**, 2, e204-11	14
1509	The natural tumorcide Manumycin-A targets protein phosphatase 1 and reduces hydrogen peroxide to induce lymphoma apoptosis. **2015**, 332, 136-45	10
1508	Regio- and enantioselective synthesis of N-substituted pyrazoles by rhodium-catalyzed asymmetric addition to allenes. **2015**, 54, 7149-53	74
1507	Przewlek bia czka limfocytowa wysokiego ryzyka. **2015**, 46, 68-74	
1506	Ibrutinib for AML? Check CD117 (KIT)!. **2015**, 2, e180-1	0
1505	Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma. **2015**, 170, 445-56	65
1504	Management of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitors. **2015**, 90, 657-64	9
1503	Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice. **2015**, 15, 385-91	22

1502	Predictors of outcome in reduced intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: summarizing the evidence and highlighting the limitations. **2015**, 7, 47-56	3
1501	[Chronic lymphocytic leukemia : treatment concepts in transition]. **2015**, 56, 374-80	
1500	The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia. **2015**, 75, 907-16	50
1499	The evolving role of hematopoietic cell transplantation in chronic lymphocytic leukemia. **2015**, 10, 18-27	1
1498	Therapeutic benefits targeting B-cells in chronic graft-versus-host disease. **2015**, 101, 438-51	17
1497	Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. **2015**, 90, 446-60	175
1496	Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma. **2015**, 75, 1675-81	74
1495	Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia. **2015**, 29, 1524-9	81
1494	Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies. **2015**, 97, 455-68	40
1493	Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?. **2015**, 8, 16	67
1492	Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia. **2015**, 125, 3688-93	28
1491	Prognosis and therapy of chronic lymphocytic leukemia and small lymphocytic lymphoma. **2015**, 165, 147-75	10
1490	Secondary mutations as mediators of resistance to targeted therapy in leukemia. **2015**, 125, 3236-45	90
1489	Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels. **2015**, 11, 252-8	77
1488	FDA-approved small-molecule kinase inhibitors. **2015**, 36, 422-39	640
1487	Chlamydophila psittaci-negative ocular adnexal marginal zone lymphomas express self polyreactive B-cell receptors. **2015**, 29, 1587-99	13
1486	Ibrutinib-associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphoma. **2015**, 170, 131-4	12
1485	Haematological malignancies: at the forefront of immunotherapeutic innovation. **2015**, 15, 201-15	55

1484	Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia. **2015**, 75, 769-76		33
1483	Regio- and Enantioselective Synthesis of N-Substituted Pyrazoles by Rhodium-Catalyzed Asymmetric Addition to Allenes. **2015**, 127, 7255-7259		39
1482	IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma. **2015**, 21, 2167-76		12
1481	The pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia. **2015**, 29, 1623-31		25
1480	The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL. **2015**, 29, 1811-22		128
1479	Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia. **2015**, 21, 3705-15		147
1478	Blinatumomab for the treatment of B-cell lymphoma. **2015**, 24, 715-24		25
1477	The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia. **2015**, 11, 51-9		18
1476	Three-year follow-up of treatment-naˆ Ïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. **2015**, 125, 2497-506		529
1475	The biology behind PI3K inhibition in chronic lymphocytic leukaemia. **2015**, 6, 25-36		7
1474	Ibrutinib in previously treated Waldenstrˆ Ïm's macroglobulinemia. *New England Journal of Medicine*, **2015**, 372, 1430-40	59.2	617
1473	Total proteome analysis identifies migration defects as a major pathogenetic factor in immunoglobulin heavy chain variable region (IGHV)-unmutated chronic lymphocytic leukemia. **2015**, 14, 933-45		25
1472	Novelties in the management of B-cell malignancies: B-cell receptor signaling inhibitors and lenalidomide. **2015**, 8, 765-83		3
1471	Nurse-like cells mediate ibrutinib resistance in chronic lymphocytic leukemia patients. **2015**, 5, e355		25
1470	Predictive biomarkers in precision medicine and drug development against lung cancer. **2015**, 34, 295-309		29
1469	Bioanalysis of ibrutinib and its active metabolite in human plasma: selectivity issue, impact assessment and resolution. **2015**, 7, 2713-24		25
1468	Cytotoxic metabolites from the endophytic fungus Penicillium chermesinum: discovery of a cysteine-targeted Michael acceptor as a pharmacophore for fragment-based drug discovery, bioconjugation and click reactions. **2015**, 5, 70595-70603		32
1467	FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia. **2015**, 21, 3586-90		90

1466	Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens. **2015**, 112, 13447-54	105
1465	Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants. **2015**, 3, e00156	64
1464	Ibrutinib in Refractory Classic Hodgkin's Lymphoma. *New England Journal of Medicine*, **2015**, 373, 1381-259.2	27
1463	Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia in Patients with Comorbidities: New Agents, New Hope. **2015**, 32, 877-86	3
1462	Ibrutinib has some activity in Richter's syndrome. **2015**, 5, e277	19
1461	What is the status of novel anti-CD20 antibodies for chronic lymphocytic leukemia and are they set to leave rituximab in the shadows?. **2015**, 8, 733-42	8
1460	Bruton's tyrosine kinase inhibitors in B-cell non-Hodgkin's lymphomas. **2015**, 97, 469-77	24
1459	Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia. **2015**, 29, 2338-46	27
1458	Disruption of pre-B-cell receptor signaling jams the WNT/□-catenin pathway and induces cell death in B-cell acute lymphoblastic leukemia cell lines. **2015**,	7
1457	Enhanced Chemokine Receptor Recycling and Impaired S1P1 Expression Promote Leukemic Cell Infiltration of Lymph Nodes in Chronic Lymphocytic Leukemia. **2015**, 75, 4153-63	32
1456	Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo. **2015**, 21, 4642-51	77
1455	The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression. **2015**, 11, 1895-903	27
1454	Panniculitis in Patients Undergoing Treatment With the Bruton Tyrosine Kinase Inhibitor Ibrutinib for Lymphoid Leukemias. **2015**, 1, 684-6	27
1453	Promising therapies for the treatment of chronic lymphocytic leukemia. **2015**, 24, 795-807	4
1452	Shifting paradigms in the treatment of chronic lymphocytic leukemia. **2015**, 11, 641-57	3
1451	PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL). **2016**, 393, 123-142	38
1450	Ibrutinib Inhibits Platelet Integrin □IIb□3 Outside-In Signaling and Thrombus Stability But Not Adhesion to Collagen. **2015**, 35, 2326-35	68
1449	The clinical safety of ibrutinib in chronic lymphocytic leukemia. **2015**, 14, 1621-9	6

1448	BTK Signaling in B Cell Differentiation and Autoimmunity. **2016**, 393, 67-105	73
1447	Lymphoma and Lymphoproliferative Disorders. **2015**, 619-644	
1446	Durability of Kinase-Directed Therapies--A Network Perspective on Response and Resistance. **2015**, 14, 1975-84	18
1445	Pharmacodynamic considerations of small molecule targeted therapy for treating B-cell malignancies in the elderly. **2015**, 11, 1371-91	5
1444	Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. **2015**, 33, 4210-8	282
1443	TLR-9 and IL-15 Synergy Promotes the In Vitro Clonal Expansion of Chronic Lymphocytic Leukemia B Cells. **2015**, 195, 901-23	25
1442	How I treat chronic lymphocytic leukemia in older patients. **2015**, 6, 333-40	5
1441	A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia. **2015**, 15, 694-8	1
1440	Searching for Drug Synergy in Complex Dose-Response Landscapes Using an Interaction Potency Model. **2015**, 13, 504-13	232
1439	Emerging therapies for refractory chronic lymphocytic leukemia. **2015**, 56, 285-92	2
1438	De novo deletion 17p13.1 as a predictor for disease progression in chronic lymphocytic leukemia. **2015**, 15, 493-9	1
1437	Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. **2015**, 56, 645-9	23
1436	miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib. **2015**, 29, 1210-3	15
1435	The genomic landscape of chronic lymphocytic leukaemia: biological and clinical implications. **2015**, 169, 14-31	22
1434	Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. **2015**, 29, 783-7	158
1433	Novel agents in the treatment of chronic lymphocytic leukemia: a review about the future. **2015**, 15, 314-22	12
1432	Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest. **2015**, 3, 37-47	22
1431	New Drugs in 2013. **2015**, 4, 128-133	

1430	BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future. **2015**, 34, 2426-36	26
1429	Investigating and targeting chronic lymphocytic leukemia metabolism with the human immunodeficiency virus protease inhibitor ritonavir and metformin. **2015**, 56, 450-9	31
1428	Paradigm shifts in the management of poor-risk chronic lymphocytic leukemia. **2015**, 56, 1626-35	
1427	B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells. **2015**, 94, 193-205	121
1426	Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation. **2015**, 21, 281-7	16
1425	Clinical activity of a new regimen combining gemcitabine and alemtuzumab in high-risk relapsed/refractory chronic lymphocytic leukemia patients. **2015**, 94, 37-42	5
1424	Single cell imaging of Bruton's tyrosine kinase using an irreversible inhibitor. **2014**, 4, 4782	28
1423	Past, present and future role of chlorambucil in the treatment of chronic lymphocytic leukemia. **2015**, 56, 1585-92	15
1422	Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis. **2015**, 56, 711-5	13
1421	Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors. **2015**, 29, 895-900	115
1420	How applicable is fludarabine, cyclophosphamide and rituximab to the elderly?. **2015**, 56, 1599-610	11
1419	19. Translating science into therapy of lymphoma. **2016**, 379-402	
1418	11. Chronic lymphocytic leukemia. **2016**, 205-228	
1417	Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas. **2016**, 6, 1-6	7
1416	Modulation of B-cell receptor and microenvironment signaling by a guanine exchange factor in B-cell malignancies. **2016**, 13, 277-85	2
1415	Identifying High-Risk Chronic Lymphocytic Leukemia: A Pathogenesis-Oriented Appraisal of Prognostic and Predictive Factors in Patients Treated with Chemotherapy with or without Immunotherapy. **2016**, 8, e2016047	5
1414	BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia. **2016**, 8, e2016011	16
1413	Practical approach to management of chronic lymphocytic leukemia. **2016**, 12, 448-56	5

1412	Combination Therapy for Chronic Lymphoid Leukemia. **2016**, 08,	
1411	Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?. **2016**, 35, e387-98	17
1410	Retour de congrˆ S Atelier international sur la leucˆ hmie lymphoˆ Ide chronique (IWCLL) 2015, Sydney. **2016**, 22, 210-217	
1409	Successful treatment of ibrutinib-associated central nervous system hemorrhage with platelet transfusion support. **2016**, 3, 27	15
1408	Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy. **2016**, 22, 6484-500	58
1407	Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia. **2016**, 7, 70623-70638	18
1406	A Novel Case of Penile Gangrene in a Patient Treated with Ibrutinib for Chronic Lymphocytic Leukemia. **2016**, 2016, 6980198	0
1405	A case report of mantle cell lymphoma manifesting as a foot lesion. **2016**, 102,	0
1404	Novel Pharmacotherapies for B-Cell Lymphomas and Leukemias. **2016**, 23, e498-520	1
1403	Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative Disorders. **2016**, 22, 34-9	23
1402	Stable isotope-labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults. **2016**, 81, 235-45	37
1401	Recent advances in therapy of chronic lymphocytic leukaemia. **2016**, 174, 351-67	17
1400	Targeting childhood, adolescent and young adult non-Hodgkin lymphoma: therapeutic horizons. **2016**, 173, 625-36	4
1399	Targeting B-cell receptor signaling in leukemia and lymphoma: how and why?. **2016**, 5, 37-53	4
1398	Targeting protein kinase C in mantle cell lymphoma. **2016**, 173, 394-403	6
1397	Targeting plasma cells: are we any closer to a panacea for diseases of antibody-secreting cells?. **2016**, 270, 78-94	6
1396	Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. **2016**, 173, 867-75	23
1395	Clinical Insights Into the Biology and Treatment of Pancreatic Cancer. **2016**, 12, 17-23	12

1394	Therapeutic Blockade of Immune Complex-Mediated Glomerulonephritis by Highly Selective Inhibition of Bruton's Tyrosine Kinase. **2016**, 6, 26164	29
1393	Targeting BTK through microRNA in chronic lymphocytic leukemia. **2016**, 128, 3101-3112	25
1392	Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. **2016**, 128, 2899-2908	52
1391	Ibrutinib in the real world patient: many lights and some shades. **2016**, 101, 1448-1450	17
1390	Advances in the treatment of chronic lymphocytic leukaemia. **2016**, 147, 447-454	
1389	Sequencing of chronic lymphocytic leukemia therapies. **2016**, 2016, 128-136	11
1388	Novel agents in chronic lymphocytic leukemia. **2016**, 2016, 137-145	13
1387	Phosphodiesterase 4 inhibitors have wide-ranging activity in B-cell malignancies. **2016**, 128, 2886-2890	17
1386	Anemia and other hematological problems in the elderly. **2016**, 523-536	
1385	Ophthalmic manifestations of leukemia. **2016**, 27, 545-551	50
1384	Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group. **2016**, 101, 1573-1580	88
1383	Targeting Stereotyped B Cell Receptors from Chronic Lymphocytic Leukemia Patients with Synthetic Antigen Surrogates. **2016**, 291, 7558-70	11
1382	Carfilzomib Triggers Cell Death in Chronic Lymphocytic Leukemia by Inducing Proapoptotic and Endoplasmic Reticulum Stress Responses. **2016**, 22, 4712-26	16
1381	Specialty pharmacy for hematologic malignancies. **2016**, 73, 797-809	9
1380	Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia. **2016**, 47, 78-83	13
1379	Tris (dibenzylideneacetone) dipalladium: a small-molecule palladium complex is effective in inducing apoptosis in chronic lymphocytic leukemia B-cells. **2016**, 57, 2409-16	12
1378	First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. **2016**, 17, 928-942	416
1377	Choosing frontline chemoimmunotherapy for CLL. **2016**, 17, 852-854	3

1376	Arylfluorosulfates Inactivate Intracellular Lipid Binding Protein(s) through Chemoselective SuFEx Reaction with a Binding Site Tyr Residue. **2016**, 138, 7353-64	146
1375	Preclinical modeling of novel therapeutics in chronic lymphocytic leukemia: the tools of the trade. **2016**, 43, 222-32	20
1374	Secondary autoimmune cytopenias in chronic lymphocytic leukemia. **2016**, 43, 300-10	16
1373	Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial. **2016**, 57, 1291-9	16
1372	Elimination of chronic lymphocytic leukemia cells in stromal microenvironment by targeting CPT with an antiangina drug perhexiline. **2016**, 35, 5663-5673	40
1371	Approaching resistance to ibrutinib in diffuse large B-cell lymphoma. **2016**, 57, 1254-5	4
1370	Ibrutinib-related atrial fibrillation in patients with mantle cell lymphoma. **2016**, 57, 2914-2916	16
1369	Altered treatment of chronic lymphocytic leukemia in Germany during the last decade. **2016**, 95, 853-61	3
1368	Elucidation of tonic and activated B-cell receptor signaling in Burkitt's lymphoma provides insights into regulation of cell survival. **2016**, 113, 5688-93	30
1367	Structure-based discovery of novel 4,5,6-trisubstituted pyrimidines as potent covalent Bruton's tyrosine kinase inhibitors. **2016**, 26, 3052-3059	9
1366	Chemical Tools To Monitor and Manipulate Adaptive Immune Responses. **2016**, 138, 6076-94	12
1365	Role of the tumor microenvironment in mature B-cell lymphoid malignancies. **2016**, 101, 531-40	52
1364	Targeting lymphoma with precision using semisynthetic anti-idiotype peptibodies. **2016**, 113, 5376-81	13
1363	Venetoclax: a new weapon to treat high-risk CLL. **2016**, 17, 690-691	7
1362	An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. **2016**, 17, 779-790	379
1361	Analysis of prognosis in CLL: collaboration makes the difference. **2016**, 17, 691-692	
1360	Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. **2016**, 127, 79-86	59
1359	Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL. **2016**, 127, 279-86	89

1358	A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. **2016**, 127, 411-9	195
1357	Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. **2016**, 127, 303-9	347
1356	Human STEAP3 mutations with no phenotypic red cell changes. **2016**, 127, 1067-71	6
1355	The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. **2016**, 127, 3215-24	181
1354	Ibrutinib responsive central nervous system involvement in chronic lymphocytic leukemia. **2016**, 127, 2356-8	19
1353	Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation in CLL. **2016**, 128, 816-26	39
1352	Second-generation inhibitors of Bruton tyrosine kinase. **2016**, 9, 80	122
1351	Chronic lymphocytic leukemia immunoglobulins display bacterial reactivity that converges and diverges from auto-/poly-reactivity and IGHV mutation status. **2016**, 172, 44-51	8
1350	Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells. **2016**, 18, 1393-1409	67
1349	Atrial fibrillation, anticoagulant stroke prophylaxis and bleeding risk with ibrutinib therapy for chronic lymphocytic leukaemia and lymphoproliferative disorders. **2016**, 175, 359-364	21
1348	[Advances in the treatment of chronic lymphocytic leukaemia]. **2016**, 147, 447-454	
1347	Rekomendacje diagnostyczne i terapeutyczne dla przewlekłej białaczki limfocytowej w 2016 r. Raport Grupy Roboczej PTHiT i PALG-CLL. **2016**, 47, 169-183	1
1346	B cell receptor inhibition as a target for CLL therapy. **2016**, 29, 2-14	8
1345	Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses. **2016**, 12, 1381-1392	23
1344	Richter's syndrome: Novel and promising therapeutic alternatives. **2016**, 29, 30-39	19
1343	The chronic lymphocytic leukemia microenvironment: Beyond the B-cell receptor. **2016**, 29, 40-53	19
1342	A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. **2016**, 57, 2212-5	10
1341	Current state of hematopoietic cell transplantation in CLL as smart therapies emerge. **2016**, 29, 54-66	5

1340	LYN Kinase in the Tumor Microenvironment Is Essential for the Progression of Chronic Lymphocytic Leukemia. **2016**, 30, 610-622	42
1339	A New Role for Lyn in the CLL Microenvironment. **2016**, 30, 511-512	2
1338	Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis. **2016**, 128, 1609-13	58
1337	Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. **2016**, 22, 2117-2125	70
1336	NF-B activation in chronic lymphocytic leukemia: A point of convergence of external triggers and intrinsic lesions. **2016**, 39, 40-8	38
1335	Molecular Pathology: Predictive, Prognostic, and Diagnostic Markers in Lymphoid Neoplasms. **2016**, 9, 489-521	3
1334	Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design. **2016** , 15, 771-785	293
1333	Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia. **2016**, 175, 641-651	18
1332	Prognostic indices in chronic lymphocytic leukaemia: where do we stand how do we proceed?. **2016** , 279, 347-57	34
1331	Chronic lymphocytic leukemia: Time to go past genomics?. **2016**, 91, 518-28	11
1330	Les actualit ˆ s marquantes du congr ˆ S Targeted Anticancer Therapies TAT 2016. **2016**, 18, 451-462	
1329	Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia. **2016**, 101, e295-8	54
1328	EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer. **2016**, 9, 59	113
1327	Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations. **2016**, 11, 2897-2907	82
1326	Metaphase Cytogenetics in Chronic Lymphocytic Leukemia. **2016**, 4, 65-73	
1325	BCR and chemokine responses upon anti-IgM and anti-IgD stimulation in chronic lymphocytic leukaemia. **2016**, 95, 1979-1988	7
1324	The potential of venetoclax (ABT-199) in chronic lymphocytic leukemia. **2016**, 7, 270-287	30
1323	Genetic evolution in chronic lymphocytic leukaemia. **2016**, 29, 67-78	1

1322	Sunitinib uptake inhibits platelet function in cancer patients. **2016**, 66, 47-54	11
1321	Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?. **2016**, 16 Suppl, S74-81	17
1320	Rewired NFB signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma. **2016**, 97, 499-510	14
1319	TP53 dysfunction in CLL: Implications for prognosis and treatment. **2016**, 29, 90-99	12
1318	Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. **2016**, 128, 2489-2496	235
1317	Transformed Lymphoma. **2016**, 30, 1317-1332	6
1316	Editing of mouse and human immunoglobulin genes by CRISPR-Cas9 system. **2016**, 7, 10934	45
1315	PI3K signaling pathway in normal B cells and indolent B-cell malignancies. **2016**, 43, 647-654	24
1314	Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. **2016**, 17, 1409-1418	233
1313	Ibrutinib holds promise for patients with 17p deletion CLL. **2016**, 17, 1342-1343	2
1312	Targeting cell adhesion and homing as strategy to cure Waldenstrˆ Ðm's macroglobulinemia. **2016**, 29, 161-168	3
1311	Principles of Chemotherapy. **2016**, 171-185.e2	
1310	Hematopoietic Cell Transplantation for Richter Syndrome. **2016**, 22, 1938-1944	9
1309	Latest Advances Towards Ras Inhibition: A Medicinal Chemistry Perspective. **2016**, 55, 15982-15988	12
1308	Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia. **2016**, 38, 346-357	17
1307	Fortschritte bei der Ras-Inhibition aus medizinisch-chemischer Perspektive. **2016**, 128, 16215-16221	
1306	Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms. **2016**, 113, 395-408	59
1305	ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells. **2016**, 127, 582-95	154

1304	BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199. **2016**, 127, 3192-201	84
1303	Pathogenic role of B-cell receptor signaling and canonical NF-B activation in mantle cell lymphoma. **2016**, 128, 82-92	92
1302	Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia. **2016**, 127, 1064-7	22
1301	Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation. **2016**, 127, 449-57	42
1300	IL-4 rescues surface IgM expression in chronic lymphocytic leukemia. **2016**, 128, 553-62	25
1299	Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance. **2016**, 11, 1681-91	38
1298	Ibrutinib, a Carboxylic Acid Amide Inhibitor of Bruton's Tyrosine Kinase. **2016**, 197-208	
1297	Toll-like receptors signaling: A complex network for NF-B activation in B-cell lymphoid malignancies. **2016**, 39, 15-25	48
1296	Brˆ Bsted acid-mediated annulations of 1-cyanocyclopropane-1-carboxylates with arylhydrazines: efficient strategy for the synthesis of 1,3,5-trisubstituted pyrazoles. **2016**, 6, 67724-67728	8
1295	Ibrutinib in Waldenstrˆ Bm macroglobulinemia: latest evidence and clinical experience. **2016**, 7, 179-86	22
1294	Maintenance therapy in CLL: resolving the controversy. **2016**, 3, e304-5	
1293	Ibrutinib as an antitumor immunomodulator in patients with refractory chronic lymphocytic leukemia. **2016**, 5, e1242544	12
1292	Targeted Therapy of CLL. **2016**, 39, 768-778	5
1291	Resistance to FLT3 Inhibitors. **2016**, 131-145	
1290	Cancer Drug Discovery. **2016**,	5
1289	Discovery of Pyrazolopyrimidine Derivatives as Novel Dual Inhibitors of BTK and PI3K**2016**, 7, 1161-1166	15
1288	Resistance to Tyrosine Kinase Inhibitors. **2016**,	1
1287	Osteolytic lesions occur rarely in patients with B-CLL and may respond well to ibrutinib. **2016**, 57, 2476-80	2

1286	Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. **2016**, 7, 11589	220
1285	Management of elderly and unfit patients with chronic lymphocytic leukemia. **2016**, 9, 1165-1175	4
1284	The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia. **2016**, 9, 1177-1187	2
1283	Is the lymphoma better? Not easy to determine. **2016**, 128, 2481-2482	1
1282	Doubly blind: a systematic review of gender in randomised controlled trials. **2016**, 9, 29597	46
1281	□2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia. **2016**, 122, 565-73	14
1280	Neue Therapiekonzepte bei der chronisch-lymphatischen Leuk□ hie. **2016**, 22, 283-294	3
1279	Paving the way for new agents; is standard chemotherapy part of the treatment paradigm for chronic lymphocytic leukemia in the future?. **2016**, 9, 679-93	2
1278	A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy. **2016**, 95, 1137-43	24
1277	Efficient bioreductive production of (S)-N-Boc-3-hydroxypiperidine using ketoreductase ChKRED03. **2016**, 51, 881-885	19
1276	The ibrutinib B-cell proliferation inhibition is potentiated in vitro by dexamethasone: Application to chronic lymphocytic leukemia. **2016**, 47, 1-7	8
1275	Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells. **2016**, 15, 2198-208	29
1274	Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinib. **2016**, 7, 157-70	22
1273	Unusual, spontaneous aneurysm formation in a patient being treated with ibrutinib for chronic lymphocytic leukemia. **2016**, 7, 231-2	3
1272	Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. **2016**, 9, 21	140
1271	Role of precision medicine in the treatment of chronic lymphocytic leukaemia. **2016**, 1, 145-154	
1270	The relation of illness perceptions to stress, depression, and fatigue in patients with chronic lymphocytic leukaemia. **2016**, 31, 891-902	14
1269	Ibrutinib in der Initialtherapie der CLL. **2016**, 19, 18-20	2

1268	Targeting tumor tolerance: A new hope for pancreatic cancer therapy?. **2016**, 166, 9-29		22
1267	Colony-Stimulating Factor-1 Receptor Is Required for Nurse-like Cell Survival in Chronic Lymphocytic Leukemia. **2016**, 22, 6118-6128		27
1266	A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib. **2016**, 22, 92-104		43
1265	The use of Bruton's tyrosine kinase inhibition as a bridging strategy to successful allogeneic stem cell transplant in relapsed mantle cell lymphoma. **2016**, 57, 461-462		1
1264	Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. **2016**, 57, 2037-46		16
1263	Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies. **2016**, 103, 86-94		24
1262	Active medulloblastoma enhancers reveal subgroup-specific cellular origins. **2016**, 530, 57-62		234
1261	Progress in Chronic Lymphocytic Leukemia with Targeted Therapy. *New England Journal of Medicine* , **2016**, 374, 386-8	59.2	5
1260	Incidence and severity of pseudohyperkalemia in chronic lymphocytic leukemia: a longitudinal analysis. **2016**, 57, 1952-5		7
1259	Targeted therapies for CLL: Practical issues with the changing treatment paradigm. **2016**, 30, 233-44		57
1258	Ibrutinib for mantle cell lymphoma. **2016**, 12, 477-91		6
1257	Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantation. **2016**, 51, 793-8		21
1256	Pitting new treatments for chronic lymphocytic leukemia against old ones: how do they fare?. **2016**, 9, 245-54		1
1255	Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study. **2016**, 22, 1572-82		130
1254	Tumor lysis syndrome: review of pathogenesis, risk factors and management of a medical emergency. **2016**, 9, 197-208		24
1253	Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. **2016**, 17, 200-211		314
1252	Ibrutinib in chronic lymphocytic leukaemia: alone or in combination?. **2016**, 17, 129-131		9
1251	Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors. **2016**, 97, 291-302		12

1250	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. *New England Journal of Medicine*, **2016**, 374, 323-32	59.2	621
1249	Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. *New England Journal of Medicine*, **2016**, 374, 311-22	59.2	1164
1248	Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia. **2016**, 152, 698-701		38
1247	Ibrutinib for treatment of chronic lymphocytic leukemia. **2016**, 73, 367-75		9
1246	Chronic lymphocytic leukemia therapy: new targeted therapies on the way. **2016**, 17, 1077-89		11
1245	Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with everolimus (RAD001) and alemtuzumab: a Phase I/II study. **2016**, 57, 1585-91		9
1244	Comment on Lipsky et al.: Incidence and Risk Factors of Bleeding-Related Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. **2016**, 101, e123		2
1243	Chronic lymphocytic leukemia (CLL)-Then and now. **2016**, 91, 330-40		83
1242	HLA mismatching as a strategy to reduce relapse after alternative donor transplantation. **2016**, 53, 57-64		37
1241	Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression. **2016**, 14, 1748-1760		69
1240	Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study. **2016**, 51, 799-806		10
1239	Progress in BCL2 inhibition for patients with chronic lymphocytic leukemia. **2016**, 43, 274-9		15
1238	Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment. **2016**, 76, 2125-36		121
1237	Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells. **2016**, 43, 291-9		12
1236	The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy. **2016**, 12, 763-73		62
1235	Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia. **2016**, 43, 265-73		14
1234	Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia. **2016**, 43, 251-9		29
1233	Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia. **2016**, 43, 280-90		21

1232	Genomic Features: Impact on Pathogenesis and Treatment of Chronic Lymphocytic Leukemia. **2016**, 39, 34-40	3
1231	Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents. **2016**, 11, 52-60	5
1230	Kinasen als Ziele molekularer Tumortherapie. **2016**, 22, 40-49	
1229	TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia. **2016**, 7, e2071	27
1228	The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. **2016**, 22, 2684-96	108
1227	The molecular pathogenesis of chronic lymphocytic leukaemia. **2016**, 16, 145-62	170
1226	Gene mutations in chronic lymphocytic leukemia. **2016**, 43, 215-21	12
1225	[Ibrutinib prescription in B-cell lymphoid neoplasms]. **2016**, 103, 127-37	0
1224	Initial therapy of chronic lymphocytic leukemia. **2016**, 43, 241-50	8
1223	Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting. **2016**, 11, 61-70	5
1222	Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function. **2016**, 310, C373-80	49
1221	Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenstr□ n macroglobulinemia. **2016**, 101, e111-5	25
1220	Richter syndrome: pathogenesis and management. **2016**, 43, 311-9	52
1219	Dogs as a Model for Cancer. **2016**, 4, 199-222	95
1218	Prognostic Factors for Chronic Lymphocytic Leukemia. **2016**, 11, 37-42	17
1217	Venetoclax Adds a New Arrow Targeting Relapsed CLL to the Quiver. **2016**, 29, 3-4	2
1216	BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia. **2016**, 30, 833-43	120
1215	CD79B limits response of diffuse large B cell lymphoma to ibrutinib. **2016**, 57, 1413-22	24

1214	B Cell Receptor Signaling. **2016**,	
1213	Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML. **2016**, 30, 754-7	26
1212	The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies. **2016**, 37, 141-153	19
1211	Sensitivity of chronic lymphocytic leukemia cells to small targeted therapeutic molecules: An in vitro comparative study. **2016**, 44, 38-49.e1	4
1210	A novel way to consolidate incomplete responses in chronic lymphocytic leukemia/small lymphocytic lymphoma. **2016**, 57, 503-4	
1209	Death by a thousand knives: Multiple BH3-only proteins are required for maximal apoptosis triggered through the BCR. **2016**, 3, e1084444	
1208	Ibrutinib-A double-edge sword in cancer and autoimmune disorders. **2016**, 24, 373-85	17
1207	Cytoplasmic myosin-exposed apoptotic cells appear with caspase-3 activation and enhance CLL cell viability. **2016**, 30, 74-85	3
1206	Antigen Selection Shapes the T-cell Repertoire in Chronic Lymphocytic Leukemia. **2016**, 22, 167-74	28
1205	Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia. **2016**, 57, 1494-7	15
1204	Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia. **2016**, 30, 346-50	61
1203	CCL3 chemokine expression by chronic lymphocytic leukemia cells orchestrates the composition of the microenvironment in lymph node infiltrates. **2016**, 57, 563-71	25
1202	Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy. **2016**, 22, 86-95	60
1201	Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment. **2016**, 1863, 401-413	125
1200	Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia. **2016**, 30, 173-81	34
1199	Ibrutinib-associated tumor lysis syndrome in a patient with mantle cell lymphoma: A case report. **2017**, 23, 235-239	4
1198	Ibrutinib monotherapy as effective treatment of central nervous system involvement by chronic lymphocytic leukaemia. **2017**, 176, 829-831	9
1197	Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia. **2017**, 31, 340-349	21

1196	Single-dose pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairment. **2017**, 58, 185-194	14
1195	Expanding the armamentarium for chronic lymphocytic leukemia: A review of novel agents in the management of chronic lymphocytic leukemia. **2017**, 23, 502-517	3
1194	Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia. **2017**, 7,	16
1193	Introduction: History of SH2 Domains and Their Applications. **2017**, 1555, 3-35	4
1192	Pseudokinases: update on their functions and evaluation as new drug targets. **2017**, 9, 245-265	49
1191	Ibrutinib: A Review in Chronic Lymphocytic Leukaemia. **2017**, 77, 225-236	46
1190	Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia. **2017**, 23, 4527-4533	43
1189	Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia. **2017**, 31, 2075-2084	104
1188	HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment. **2017**, 36, 3441-3449	16
1187	Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. **2017**, 129, 1469-1479	196
1186	Lipids and Their Effects in Chronic Lymphocytic Leukemia. **2017**, 15, 2-3	2
1185	Protein-ligand (un)binding kinetics as a new paradigm for drug discovery at the crossroad between experiments and modelling. **2017**, 8, 534-550	51
1184	Pathways and mechanisms of venetoclax resistance. **2017**, 58, 1-17	102
1183	How I manage patients with hairy cell leukaemia. **2017**, 177, 543-556	24
1182	Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. **2017**, 23, 1149-1155	43
1181	BTK-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. **2017**, 35, 1437-1443	245
1180	Update of the Grupo Espaˆ –ol de Leucemia Linfocˆ Eica Crˆ Eica clinical guidelines of the management of chronic lymphocytic leukemia. **2017**, 148, 381.e1-381.e9	1
1179	A Concise Review of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia. **2017**, 12, 29-38	26

1178	Human NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase. **2017**, 140, 1054-1067.e10	72
1177	Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia. **2018**, 249, 203-229	5
1176	Distinct and Overlapping Functions of TEC Kinase and BTK in B Cell Receptor Signaling. **2017**, 198, 3058-3068	10
1175	Development of a practical biocatalytic process for (S)-N-Boc-3-hydroxypiperidine synthesis. **2017**, 58, 1644-1650	12
1174	What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017?. **2017**, 18, 12	6
1173	Targeted Therapy in Chronic Lymphocytic Leukemia (CLL). **2017**, 12, 20-28	6
1172	Novel agents versus chemotherapy as frontline treatment of CLL. **2017**, 58, 1320-1324	3
1171	Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia. **2017**, 58, 2356-2362	6
1170	Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. **2017**, 8, 14175	54
1169	Magic pills: new oral drugs to treat chronic lymphocytic leukemia. **2017**, 18, 411-425	6
1168	Current Treatment of Chronic Lymphocytic Leukemia. **2017**, 18, 5	14
1167	Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells. **2017**, 542, 489-493	88
1166	Cancer: A targeted treatment with off-target risks. **2017**, 542, 424-425	14
1165	Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. **2017**, 178, 286-291	47
1164	MYC Protein-positive Diffuse Large B-Cell Lymphoma Features an Activated B-Cell Receptor Signal Pathway. **2017**, 41, 541-549	5
1163	Lenalidomide in the treatment of chronic lymphocytic leukemia. **2017**, 26, 633-650	25
1162	Milestones in´ Chronic Lymphocytic Leukemia: An exciting decade of progress-10th anniversary of. **2017**, 10, 8-12	
1161	Characterization of Covalent-Reversible EGFR Inhibitors. **2017**, 2, 1563-1575	11

1160	Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. **2017**, 129, 3419-3427	244
1159	Targeting ROR1 identifies new treatment strategies in hematological cancers. **2017**, 45, 457-464	22
1158	Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study. **2017**, 92, 759-763	16
1157	Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. **2017**, 8, 14920	85
1156	Rituximab and Alemtuzumab for Chronic Lymphocytic Leukemia: Clinical Pharmacology and Therapeutic Results. **2017**, 99-122	
1155	Clinical chemoproteomics-Opportunities and obstacles. **2017**, 9,	17
1154	Advances in the role of cytogenetic analysis in the molecular diagnosis of B-cell lymphomas. **2017**, 17, 623-632	2
1153	USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status. **2017**, 130, 156-166	41
1152	Venetoclax for the treatment of patients with chronic lymphocytic leukemia. **2017**, 13, 1223-1232	7
1151	The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia. **2017**, 58, 2287-2297	7
1150	Comparative genomic expression signatures of signal transduction pathways and targets in paediatric Burkitt lymphoma: a Children's Oncology Group report. **2017**, 177, 601-611	13
1149	Small-Molecule Inhibitors of Bruton□ Tyrosine Kinase. **2017**, 75-104	1
1148	Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition. **2017**, 31, 2601-2607	15
1147	Real-world results of ibrutinib in relapsed/refractory CLL in France: Early results on a large series of 428 patients. **2017**, 92, E166-E168	20
1146	Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma. **2017**, 12, 207-216	10
1145	2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors. **2017**, 135, 531-543	14
1144	An update for Richter syndrome - new directions and developments. **2017**, 178, 508-520	23
1143	Chronic lymphocytic leukaemia genomics and the precision medicine era. **2017**, 178, 852-870	10

1142	Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia. **2017**, 18, 857-873	2
1141	Restrictions in the T-cell repertoire of chronic lymphocytic leukemia: high-throughput immunoprofiling supports selection by shared antigenic elements. **2017**, 31, 1555-1561	28
1140	Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib. **2017**, 31, 1117-1122	33
1139	Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib. **2017**, 31, 1333-1339	57
1138	Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. **2017**, 7, 1018-1029	201
1137	Drug discovery and therapeutic delivery for the treatment of B and T cell tumors. **2017**, 114, 285-300	14
1136	Update of the Grupo Espaˆ –ol de Leucemia Linfocˆ Ïica Crˆ Ïica clinical guidelines of the management of chronic lymphocytic leukemia. **2017**, 148, 381.e1-381.e8	
1135	The Promise and the Hype of 'Personalised Medicine'. **2017**, 23, 13-20	24
1134	Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. **2017**, 28, 2169-2178	157
1133	The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia. **2017**, 16, 1079-1088	9
1132	Genetic landscape and deregulated pathways in B-cell lymphoid malignancies. **2017**, 282, 371-394	41
1131	Ibrutinib-induced severe liver injury. **2017**, 5, 735-738	7
1130	Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies. **2017**, 34, 509-527	27
1129	Bruton's tyrosine kinase (BTK) as a promising target in solid tumors. **2017**, 58, 41-50	68
1128	Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative Activity. **2017**, 429, 2211-2230	25
1127	Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis. **2017**, 58, 2981-2982	48
1126	Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. **2017**, 28, 1050-1056	139
1125	Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma. **2017**, 10, 80	8

1124	Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition. **2017**, 36, 4653-4661	21
1123	Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059. **2017**, 129, 2808-2810	39
1122	Lymphoid Leukaemias of Mature B, T and Natural Killer Cells. **2017**, 417-524	1
1121	Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia. **2017**, 21, 27-29	45
1120	Successful use of Bruton's kinase inhibitor, ibrutinib, to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukaemia. **2017**, 58, e240-e242	20
1119	Choosing and sequencing novel drugs in CLL: dealing with an embarrassment of riches?. **2017**, 28, 920-921	0
1118	Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia. **2017**, 96, 1185-1196	20
1117	Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity. **2017**, 140, 875-879.e1	27
1116	Ibrutinib-resistant CLL: unwanted and unwonted!. **2017**, 129, 1407-1409	5
1115	Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax. **2017**, 56, 1255-1266	9
1114	Targeted therapy in the treatment of chronic lymphocytic leukemia: facts, shortcomings and hopes for the future. **2017**, 10, 425-432	3
1113	Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib. **2017** , 96, 1175-1184	37
1112	Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival. **2017**, 177, 567-577	5
1111	Targeting of B-cell receptor signalling in B-cell malignancies. **2017**, 282, 415-428	29
1110	Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia. **2017**, 8, 14756	44
1109	Dual Inhibition of Bruton's Tyrosine Kinase and Phosphoinositide-3-Kinase p110 as a Therapeutic Approach to Treat Non-Hodgkin's B Cell Malignancies. **2017**, 361, 312-321	5
1108	Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial. **2017**, 176, 412-420	43
1107	Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199). **2017**, 31, 1872-1881	46

1106 Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells. **2017**, 23, 3734-3743 82

1105 Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling. **2017**, 129, 759-770 52

1104 The role of combined fludarabine, cyclophosphamide and rituximab chemoimmunotherapy in chronic lymphocytic leukemia: current evidence and controversies. **2017**, 8, 99-105 16

1103 Chronic lymphocytic leukemia and small lymphocytic lymphoma: two faces of the same disease. **2017**, 10, 137-146 10

1102 Flow cytometry minimal residual disease after allogeneic transplant for chronic lymphocytic leukemia. **2017**, 98, 363-370 8

1101 NFAT2 is a critical regulator of the anergic phenotype in chronic lymphocytic leukaemia. **2017**, 8, 755 24

1100 Venetoclax for the treatment of chronic lymphocytic leukemia. **2017**, 26, 1307-1316 39

1099 MALT1 Inhibition Is Efficacious in Both Naˆ Ïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia. **2017**, 77, 7038-7048 33

1098 In Silico Identification of a Novel Hinge-Binding Scaffold for Kinase Inhibitor Discovery. **2017**, 60, 8552-8564 20

1097 Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia. **2017**, 26, 1249-1265 27

1096 Maintenance lenalidomide could be most relevant after first-line therapy. **2017**, 4, e502-e503

1095 [State of the art molecular diagnostics and therapy of chronic lymphocytic leukaemia in the era of new targeted therapies]. **2017**, 158, 1620-1629

1094 Selected miRNA levels are associated with microdeletions in pediatric acute lymphoblastic leukemia. **2017**, 14, 3853-3861 7

1093 Combination therapy with the type II anti-CD20 antibody obinutuzumab. **2017**, 26, 1145-1162 4

1092 Will combination therapy with targeted drugs be better for achieving remission in chronic lymphocytic leukemia?. **2017**, 18, 1675-1678 1

1091 Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor. **2017**, 60, 7725-7744 14

1090 Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents. **2017**, 22, 1283-1291 39

1089 Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile. **2017**, 363, 240-252 198

1088	Concept of Combining Cost-Effectiveness Analysis and Budget Impact Analysis in Health Care Decision-Making. **2017**, 13, 61-66	7
1087	Imbruvica?(ibrutinib) patient support programme for chronic lymphocytic leukaemia and mantle cell lymphoma. **2017**, 26, S20-S25	1
1086	What Is the Role of Chemotherapy in Patients With Chronic Lymphocytic Leukemia?. **2017**, 17, 723-727	4
1085	Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies. **2017**, 17, 834-851	32
1084	Ibrutinib may impair serological responses to influenza vaccination. **2017**, 102, e397-e399	59
1083	Targeting B Cell Signaling in Chronic Lymphocytic Leukemia. **2017**, 19, 61	13
1082	Chimeric Antigen Receptor T-Cell Therapy for Chronic Lymphocytic Leukemia: A Narrative Review. **2017**, 17, 852-856	7
1081	The Clinical Spectrum of Hepatic Manifestations in Chronic Lymphocytic Leukemia. **2017**, 17, 863-869	8
1080	Bruton Tyrosine Kinase Inhibition Attenuates Liver Damage in a Mouse Warm Ischemia and Reperfusion Model. **2017**, 101, 322-331	19
1079	Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. **2017**, 92, 946-965	177
1078	Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in the General Community: A´ Single-center Experience. **2017**, 17S, S53-S61	9
1077	A Small Molecule Inhibitor of Bruton's Tyrosine Kinase Involved in B-Cell Signaling. **2017**, 2, 4398-4410	5
1076	The PI3K Pathway in Human Disease. **2017**, 170, 605-635	1030
1075	Cancer Clonal Theory, Immune Escape, and Their Evolving Roles in Cancer Multi-Agent Therapeutics. **2017**, 19, 66	6
1074	Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach. **2017**, 102, 1629-1639	93
1073	Pathways towards indolent B-cell lymphoma - Etiology and therapeutic strategies. **2017**, 31, 426-435	6
1072	Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia. **2017**, 8, 153	29
1071	New drug discovery approaches targeting recurrent mutations in chronic lymphocytic leukemia. **2017**, 12, 1041-1052	2

1052	Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia. **2017**, 23, 1049-1059	28
1051	Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies. **2017**, 23, 1186-1192	20
1050	Risk of Atrial Fibrillation and Bleeding Diathesis Associated With Ibrutinib Treatment: A Systematic Review and Pooled Analysis of Four Randomized Controlled Trials. **2017**, 17, 31-37.e13	64
1049	From identification of the BTK kinase to effective management of leukemia. **2017**, 36, 2045-2053	38
1048	Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms. **2017**, 31, 246-248	73
1047	Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review. **2017**, 2, 108-123	42
1046	How to unleash mitochondrial apoptotic blockades to kill cancers?. **2017**, 7, 18-26	37
1045	Waldenstr^ ?n? Macroglobulinemia. **2017**,	
1044	Anti-tumor efficacy study of the Bruton's tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO/GS-4059 in combination with rituximab. **2017**, 58, 699-707	14
1043	Signal Inhibitors in Waldenstrom? Macroglobulinemia. **2017**, 327-334	
1042	PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers. **2017**, 57, 194-210	13
1041	Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). **2017**, 58, 1630-1639	71
1040	Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial. **2017**, 58, 1640-1647	8
1039	The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy. **2017**, 8, 2185	99
1038	[Allogeneic haematopoietic cell transplantation for indolent lymphomas: Guidelines from the Francophone Society Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. **2017**, 104, S121-S130	
1037	Successful Treatment of Richter Transformation with Ibrutinib in a Patient with Chronic Lymphocytic Leukemia following Allogeneic Hematopoietic Stem Cell Transplant. **2017**, 10, 534-541	10
1036	Hematopoietic Cell Transplants for Hodgkin Lymphoma. 361-371	
1035	Hematopoietic Cell Transplants for Chronic Lymphocytic Leukemia: Changing Landscape?. 372-383	

1034	Somatic Hypermutational Status and Gene Repertoire of Immunoglobulin Rearrangements in Chronic Lymphocytic Leukemia. **2017**,	1
1033	. **2017**,	12
1032	Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL. **2017**, 1, 715-727	74
1031	Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis. **2017**, 1, 772-778	64
1030	Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib. **2017**, 1, 1584-1588	23
1029	How should we sequence and combine novel therapies in CLL?. **2017**, 2017, 346-353	14
1028	Cancer Biology and the Principles of Targeted Cancer Drug Discovery. **2017**, 1-38	1
1027	Novel Intra-cellular Targeting Agents in Rheumatic Disease. **2017**, 1044-1060	1
1026	Ibrutinib. **2017**, 609-637	1
1025	Overview. **2017**, 641-693	
1024	Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models. **2017**, 8, 829	119
1023	Disseminated Cryptococcosis With Brain Involvement in Patients With Chronic Lymphoid Malignancies on Ibrutinib. **2017**, 4, ofw261	40
1022	Complications and management of coagulation disorders in leukemia patients. **2017**, 7, 61-72	6
1021	Syk inhibitors in clinical development for hematological malignancies. **2017**, 10, 145	79
1020	High expression of Bruton's tyrosine kinase (BTK) is required for EGFR-induced NF-Ƀ activation and predicts poor prognosis in human glioma. **2017**, 36, 132	25
1019	Atypical Infections in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Patients Treated with Ibrutinib. **2017**, 07,	
1018	Ibrutinib treatment of a patient with relapsing chronic lymphocytic leukemia and sustained remission of Richter syndrome. **2017**, 103, e37-e40	3
1017	Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib. **2017**, 2, e89904	57

1016	Covalent Kinase Inhibitors for Cancer. **2017**, 76-103	
1015	Spotlight on ibrutinib and its potential in frontline treatment of chronic lymphocytic leukemia. **2017**, 10, 1909-1914	5
1014	The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages. **2017**, 8, 39218-39229	50
1013	Ibrutinib-Associated Skin Toxicity: A Case of Maculopapular Rash in a 79-Year Old Caucasian Male Patient with Relapsed Waldenstrom's Macroglobulinemia and Review of the Literature. **2017**, 9, 6976	14
1012	Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. **2017**, 1, 1739-1748	85
1011	Clinical Applications of the Genomic Landscape of Aggressive Non-Hodgkin Lymphoma. **2017**, 35, 955-962	32
1010	Serum LDH level may predict outcome of chronic lymphocytic leukemia patients with a 17p deletion: a retrospective analysis of prognostic factors in China. **2017**, 29, 156-165	5
1009	Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. **2017**, 35, 3010-3020	396
1008	Clinical Implications of Novel Genomic Discoveries in Chronic Lymphocytic Leukemia. **2017**, 35, 984-993	37
1007	Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network. **2017**, 35, 2008-2017	98
1006	Deciphering Ibrutinib Resistance in Chronic Lymphocytic Leukemia. **2017**, 35, 1451-1452	4
1005	The effects of DLEU1 gene expression in Burkitt lymphoma (BL): potential mechanism of chemoimmunotherapy resistance in BL. **2017**, 8, 27839-27853	29
1004	Managing Patients With TP53-Deficient Chronic Lymphocytic Leukemia. **2017**, 13, 371-377	14
1003	The □secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells. **2017**, 8, 59235-59245	13
1002	Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab. **2017**, 8, 41-54	5
1001	Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development. **2018**, 61, 2227-2245	119
1000	Chronic lymphocytic leukaemia. **2018**, 391, 1524-1537	142
999	Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. **2018**, 4, 712-716	19

998	Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. **2018**, 36, 624-632	36
997	Prognostic Factors in the Era of Targeted Therapies in CLL. **2018**, 13, 78-90	7
996	The bone marrow microenvironment in health and disease at a glance. **2018**, 131,	38
995	Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia. **2018**, 59, 2686-2691	10
994	Idelalisib rapidly improves platelet function tests in patients with chronic lymphocytic leukaemia. **2018**, 183, 825-828	3
993	Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study. **2018**, 131, 2357-2366	120
992	Risk of hepatitis B virus reactivation in patients treated with ibrutinib. **2018**, 131, 1987-1989	29
991	Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer. **2018**, 67, 687-692	170
990	Standing up to the cardiometabolic consequences of hematological cancers. **2018**, 32, 349-360	3
989	ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). **2018**, 24 Suppl 2, S53-S70	93
988	Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. **2018**, 103, 1209-1217	24
987	Kinase Inhibitor Drugs. **2018**, 65-93	1
986	Venetoclax after idelalisib: relevant progress for CLL. **2018**, 131, 1632-1633	4
985	Renal involvement in chronic lymphocytic leukemia. **2018**, 11, 670-680	20
984	Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. **2018**, 103, 874-879	219
983	Ublituximab for the treatment of CD20 positive B-cell malignancies. **2018**, 27, 407-412	23
982	Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility. **2018**, 9, 89-105	10
981	BTK Inhibitors: Focus on Ibrutinib and Similar Agents. **2018**, 1-22	

980	Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study. **2018**, 7, 1043-1055	20
979	Monitoring and Management of Toxicities of Novel B Cell Signaling Agents. **2018**, 20, 49	14
978	Quercetin Therapy for Selected Patients with PIM1 Kinase-Positive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pilot Study. **2018**, 139, 132-139	7
977	Non-Hodgkin Lymphoma in Adults. **2018**, 444-462	
976	Transformation of chronic lymphocytic leukemia into B-cell acute lymphoblastic leukemia. **2018**, 131, 1258-1261	6
975	Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma. **2018**, 65, 41-46	20
974	CD19-specific chimeric antigen receptor-modified (CAR)-T cell therapy for the treatment of chronic lymphocytic leukemia in the ibrutinib era. **2018**, 10, 251-254	4
973	Patient Derived Xenografts (PDX) for personalized treatment of pancreatic cancer: emerging allies in the war on a devastating cancer?. **2018**, 188, 107-118	13
972	BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor. **2018**, 8, 458-477	67
971	Encyclopedia of Signaling Molecules. **2018**, 522-522	
970	Single-agent ibrutinib in treatment-naˆ e and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. **2018**, 131, 1910-1919	267
969	Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. **2018**, 131, 1955-1959	176
968	Targeting B cell receptor signalling in cancer: preclinical and clinical advances. **2018**, 18, 148-167	159
967	Heterologous pathway assembly reveals molecular steps of fungal terreic acid biosynthesis. **2018**, 8, 2116	14
966	Adverse Effects Associated with Clinical Applications of CAR Engineered T Cells. **2018**, 66, 283-288	2
965	Epigenetic deregulation in chronic lymphocytic leukemia: Clinical and biological impact. **2018**, 51, 1-11	26
964	Effective management strategies for patients with marginal zone lymphoma. **2018**, 14, 1213-1222	10
963	Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies. **2018**, 100, 325-334	82

962	Ibrutinib and its use in the treatment of chronic lymphocytic leukemia. **2018**, 14, 681-697	
961	and evidence for uncoupling of B-cell receptor internalization and signaling in chronic lymphocytic leukemia. **2018**, 103, 497-505	6
960	How I treat CLL patients with ibrutinib. **2018**, 131, 379-386	74
959	p66Shc deficiency enhances CXCR4 and CCR7 recycling in CLL B cells by facilitating their dephosphorylation-dependent release from □-arrestin at early endosomes. **2018**, 37, 1534-1550	16
958	Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia. **2018**, 215, 681-697	41
957	Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice. **2018**, 180, 666-679	38
956	Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia. **2018**, 9, 3-19	16
955	Tumor necrosis factor receptor signaling is a driver of chronic lymphocytic leukemia that can be therapeutically targeted by the flavonoid wogonin. **2018**, 103, 688-697	13
954	Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS study. **2018**, 59, 2075-2084	7
953	Autoimmunity checkpoints as therapeutic targets in B cell malignancies. **2018**, 18, 103-116	29
952	Critical molecular pathways in CLL therapy. **2018**, 24, 9	23
951	Role of Bruton's tyrosine kinase in B cells and malignancies. **2018**, 17, 57	225
950	DNA damage pathways and B-cell lymphomagenesis. **2018**, 25, 315-322	5
949	Infections in patients with chronic lymphocytic leukaemia: Mitigating risk in the era of targeted therapies. **2018**, 32, 499-507	37
948	Ibrutinib: coming of age?. **2018**, 131, 1880-1882	3
947	Biology and treatment of Richter syndrome. **2018**, 131, 2761-2772	87
946	Target identification reveals protein arginine methyltransferase 1 is a potential target of phenyl vinyl sulfone and its derivatives. **2018**, 38,	5
945	Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies. **2018**, 19, 636-643	8

944	Minimal residual disease analysis in chronic lymphocytic leukemia: a way for achieving more personalized treatments. **2018**, 32, 1307-1316	14
943	Bleeding and Thrombosis in Hematologic Neoplasia. **2018**, 1263-1289	1
942	The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review. **2018**, 151, 315-326	84
941	CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia. **2018**, 14, 499-513	20
940	Treatment of Chronic Lymphocytic Leukemia and Related Disorders. **2018**, 117-134	
939	Discovery and biological evaluation of N5-substituted 6,7-dioxo-6,7-dihydropteridine derivatives as potent Bruton's tyrosine kinase inhibitors. **2018**, 9, 697-704	5
938	Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management. **2018**, 180, 164-166	34
937	Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced-dose ibrutinib: results from a multi-centre study. **2018**, 181, 259-261	36
936	Severe pneumonia associated with ibrutinib monotherapy for CLL and lymphoma. **2018**, 36, 349-354	24
935	Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management. **2018**, 59, 311-320	29
934	Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia. **2018**, 59, 300-310	4
933	Treatment of Del17p and/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies. **2018**, 11, 1-12	5
932	Minimal Residual Disease in Chronic Lymphocytic Leukemia in the Era of Novel Agents: A Review. **2018**, 4, 394-400	29
931	Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen. **2018**, 59, 931-940	16
930	Ibrutinib-induced rapid response in chemotherapy-refractory Richter's syndrome. **2018**, 36, 370-371	8
929	Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature. **2018**, 24, 544-549	8
928	Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways. **2018**, 66, 140-148	165
927	Allogeneic Hematopoietic Cell Transplantation for Richter Syndrome: A Single-Center Experience. **2018**, 18, e35-e39	12

926	Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. **2018**, 131, 182-190	92
925	Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies. **2018**, 97, 1-15	26
924	Self-limiting Ibrutinib-Induced Neutrophilic Panniculitis. **2018**, 40, e28-e29	13
923	Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway. **2018**, 32, 960-970	76
922	Ibrutinib as salvage therapy in mantle cell lymphoma with central nervous system involvement in a pretreated unfit patient. **2018**, 59, 1734-1737	1
921	Clinical Practice Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL) in The Netherlands. **2018**, 18, 52-57	5
920	Highly selective SYK inhibitor, GSK143, abrogates survival signals in chronic lymphocytic leukaemia. **2018**, 182, 927-930	0
919	Targeting the Architecture of Deregulated Protein Complexes in Cancer. **2018**, 111, 101-132	4
918	Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer. **2018**, 67, 1780-1792	15
917	NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib. **2018**, 142, 322-333	24
916	Regulation of MAPK signaling and implications in chronic lymphocytic leukemia. **2018**, 59, 1565-1573	8
915	Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors. **2018**, 59, 1554-1564	29
914	Ibrutinib and idelalisib block immunophenotypic changes associated with the adhesion and activation of CLL cells in the tumor microenvironment. **2018**, 59, 1927-1937	4
913	Reduced intensity is preferred over myeloablative conditioning allogeneic HCT in chronic lymphocytic leukemia whenever indicated: A systematic review/meta-analysis. **2018**, 11, 53-64	8
912	Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. **2018**, 19, 65-75	228
911	The role of ibrutinib in Waldenstr^ Ĥn macroglobulinemia. **2018**, 6, 85-89	
910	Advances in chronic lymphocytic leukemia pharmacotherapy. **2018**, 97, 349-358	5
909	Using prognostic models in CLL to personalize approach to clinical care: Are we there yet?. **2018**, 32, 159-166	8

908	Early Phase Cancer Immunotherapy. **2018**,	1
907	Cellular Therapy. **2018**, 133-184	
906	Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy. **2018**, 59, 2287-2296	4
905	Functional Characterization of 22 CYP3A4 Protein Variants to Metabolize Ibrutinib In Vitro. **2018**, 122, 383-387	12
904	Novel agents for relapsed and refractory follicular lymphoma. **2018**, 31, 41-48	16
903	Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL). **2018**, 27, 31-42	45
902	Microenvironmental stromal cells abrogate NF-Β inhibitor-induced apoptosis in chronic lymphocytic leukemia. **2018**, 103, 136-147	11
901	Apoptosis signaling and BCL-2 pathways provide opportunities for novel targeted therapeutic strategies in hematologic malignances. **2018**, 32, 8-28	41
900	A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL. **2018**, 2, 762-768	13
899	Approaches to Chronic Lymphocytic Leukemia Therapy in the Era of New Agents: The Conundrum of Many Options. **2018**, 38, 580-591	12
898	Mechanisms of Drug Resistance in Cancer Therapy. **2018**,	
897	Relapsed CLL: sequencing, combinations, and novel agents. **2018**, 2018, 248-255	7
896	empyema in a patient receiving ibrutinib for diffuse large B-cell lymphoma and a review of the literature. **2018**, 2018,	8
895	On the architecture of translational research designed to control chronic lymphocytic leukemia. **2018**, 2018, 1-8	6
894	The Role of Bruton's Tyrosine Kinase in Immune Cell Signaling and Systemic Autoimmunity. **2018**, 38, 17-62	53
893	BENDAMUSTINE: AN OLD DRUG IN THE NEW ERA FOR PATIENTS WITH NON-HODGKIN LYMPHOMAS AND CHRONIC LYMPHOCYTIC LEUKEMIA. **2018**, 57, 542-553	5
892	Encouraging Effects of Ethacrynic Acid Derivatives Possessing a Privileged ˆ □□–, ˆ □□□-Unsaturated Carbonyl Structure Scaffold. **2018**, 08,	1
891	Hematologic Tumor Cell Resistance to the BCL-2 Inhibitor Venetoclax: A Product of Its Microenvironment?. **2018**, 8, 458	15

890	aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics. **2018**, 103, 1956-1968	43
889	Molecular Interactions Between Innate and Adaptive Immune Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications. **2018**, 9, 2720	15
888	Is less equal with ibrutinib dose?. **2018**, 132, 2211-2212	1
887	Ibrutinib-related bleeding: pathogenesis, clinical implications and management. **2018**, 29, 481-487	15
886	From Basic Knowledge to Effective Therapies. **2018**, 34, 871-873	2
885	Toward the potential cure of leukemias in the next decade. **2018**, 124, 4301-4313	20
884	A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. **2018**, 132, 2249-2259	63
883	Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. **2018**, 50, 1399-1411	94
882	Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk. **2018**, 28, 3419-3424	9
881	A Case of Bing-Neel Syndrome Successfully Treated with Ibrutinib. **2018**, 2018, 8573105	4
880	Chronic lymphocytic leukemia treatment algorithm 2018. **2018**, 8, 93	46
879	Novel agents in the Canadian therapeutic landscape of chronic lymphocytic leukemia. **2018**, 1, 7-10	1
878	Ibrutinib for chronic lymphocytic leukemia: international experience from a named patient program. **2018**, 103, e204-e206	7
877	Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies. **2018**, 78, 1653-1663	25
876	Identification of Distinct Unmutated Chronic Lymphocytic Leukemia Subsets in Mice Based on Their T Cell Dependency. **2018**, 9, 1996	6
875	Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation. **2018**, 97, 2269-2278	18
874	BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis. **2018**, 197, 205-218	16
873	Design and Synthesis of Novel Amino-triazine Analogues as Selective Bruton's Tyrosine Kinase Inhibitors for Treatment of Rheumatoid Arthritis. **2018**, 61, 8917-8933	20

872	Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p. **2018**, 2, 1946-1956	21
871	Analysis of Genomic Alteration in Primary Central Nervous System Lymphoma and the Expression of Some Related Genes. **2018**, 20, 1059-1069	23
870	The Genomic Landscape of Chronic Lymphocytic Leukaemia: Clinical Implications. **2018**, 18, S112-S115	1
869	The Antigen Receptor as a Driver of B-Cell Lymphoma Development and Evolution. **2018**,	1
868	Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia. **2018**, 18, S19-S20	
867	The Chemoimmunotherapy Era in CLL is Over. **2018**, 18, S116-S119	
866	Ibrutinib-Associated Atrial Fibrillation. **2018**, 4, 1491-1500	70
865	Selecting Frontline Therapy for CLL in 2018. **2018**, 2018, 242-247	12
864	Genomikus kˆ piaszˆ m-eltˆ rˆ sek szr ˆ se krˆ nikus limfoid leukˆ miˆ ban multiplex ligˆ ciˆ fˆ gg szondaamplifikˆ ciˆ val. **2018**, 51, 31-40	
863	BCL2 Inhibitors: Insights into Resistance. **2018**, 23-43	
862	Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia. **2018**, 59, 2792-2800	25
861	Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. **2018**, 32, 2388-2398	17
860	Evolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapy. **2018**, 15, 510-527	73
859	Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma. **2018**, 23, 111-122	14
858	Ibrutinib inactivates BMX-STAT3 in glioma stem cells to impair malignant growth and radioresistance. **2018**, 10,	62
857	Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation. **2018**, 57, 3564-3575	169
856	A drug-drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies. **2018**, 59, 2888-2895	24
855	Targeting the B cell receptor pathway in non-Hodgkin lymphoma. **2018**, 27, 513-522	29

854	Acquired platelet antagonism: off-target antiplatelet effects of malignancy treatment with tyrosine kinase inhibitors. **2018**, 16, 1686-1699	20
853	Development of an Efficient Manufacturing Process for Reversible Bruton Tyrosine Kinase Inhibitor GDC-0853. **2018**, 22, 978-990	12
852	Sensitive Detection of the Natural Killer Cell-Mediated Cytotoxicity of Anti-CD20 Antibodies and Its Impairment by B-Cell Receptor Pathway Inhibitors. **2018**, 2018, 1023490	12
851	Balancing efficacy and toxicity of targeted agents currently used for the treatment of patients with chronic lymphocytic leukemia. **2018**, 11, 601-611	8
850	Auranofin Enhances Ibrutinib's Anticancer Activity in EGFR-Mutant Lung Adenocarcinoma. **2018**, 17, 2156-2163	23
849	First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenstr ˆ Macroglobulinemia. **2018**, 32, 853-864	3
848	Insight into origins, mechanisms, and utility of DNA methylation in B-cell malignancies. **2018**, 132, 999-1006	16
847	New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?. **2018**, 11, 749-756	6
846	Resistance of Targeted Therapies Excluding Antibodies for Lymphomas. **2018**,	
845	Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies. **2018**, 72, 697-698	55
844	The effect of Bruton's tyrosine kinase (BTK) inhibitors on collagen-induced platelet aggregation, BTK, and tyrosine kinase expressed in hepatocellular carcinoma (TEC). **2018**, 101, 604	26
843	Small Molecules in Hematology. **2018**,	4
842	Dasatinib. **2018**, 212, 29-68	23
841	Ibrutinib. **2018**, 212, 133-168	19
840	Chronic Lymphocytic Leukemia. **2018**, 1244-1264	2
839	Risk of Major Bleeding with Ibrutinib. **2018**, 18, 755-761	39
838	NOTCH1 Aberrations in Chronic Lymphocytic Leukemia. **2018**, 8, 229	26
837	Responses to the Selective Bruton's Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines. **2018**, 10,	16

836	Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathways. **2018**, 103, 2069-2078	13
835	Delineating the role of cooperativity in the design of potent PROTACs for BTK. **2018**, 115, E7285-E7292	177
834	Targeting Wnt signaling pseudokinases in hematological cancers. **2018**, 101, 457-465	9
833	Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement. **2018**, 23, 919-929	13
832	Emerging Therapies and Future Directions in Targeting the Tumor Stroma and Immune System in the Treatment of Pancreatic Adenocarcinoma. **2018**, 10,	12
831	Guideline for the treatment of chronic lymphocytic leukaemia: A British Society for Haematology Guideline. **2018**, 182, 344-359	20
830	Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL. **2018**, 132, 1039-1049	32
829	High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. **2018**, 132, 892-902	64
828	Cells, cytokines, chemokines, and cancer stress: A biobehavioral study of patients with chronic lymphocytic leukemia. **2018**, 124, 3240-3248	16
827	Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors. **2018**, 351, e1700369	18
826	Highly selective inhibition of Bruton's tyrosine kinase attenuates skin and brain disease in murine lupus. **2018**, 20, 10	25
825	The diagnosis and treatment of primary vitreoretinal lymphoma: a review. **2018**, 4, 18	54
824	A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era. **2018**, 132, 521-532	56
823	Use of acalabrutinib in patients with mantle cell lymphoma. **2018**, 11, 495-502	6
822	Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia. **2018**, 132, 1568-1572	81
821	Naturally-Occurring Canine Invasive Urothelial Carcinoma: A Model for´ Emerging Therapies. **2018**, 4, 149-159	19
820	First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. **2018**, 9, 13023-13035	45
819	Duvelisib, an oral dual PI3K-□inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study. **2018**, 93, 1318-1326	33

818	Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. **2018**, 93, 1394-1401	37
817	Remission maintenance treatment options in chronic lymphocytic leukemia. **2018**, 70, 56-66	1
816	Small-Molecule Inhibitors for the Treatment of Diffuse Large B Cell Lymphoma. **2018**, 13, 356-368	9
815	Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. **2018**, 19, 1215-1228	70
814	Population Dynamics and Evolution of Cancer Cells. **2018**, 3-35	
813	The latest developments with anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia. **2018**, 18, 973-982	7
812	Dynamic changes in HLA-DR expression during short-term and long-term ibrutinib treatment in patients with chronic lymphocytic leukemia. **2018**, 72, 113-119	4
811	Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naˆ Ve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies. **2018**, 93, 1402-1410	19
810	Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. **2018**, 18, 803-813.e7	27
809	Still a role for second-line chemoimmunotherapy in chronic lymphocytic leukemia?. **2018**, 103, 1096-1098	1
808	Distinct Activities of Glycolytic Enzymes Identify Chronic Lymphocytic Leukemia Patients with a more Aggressive Course and Resistance to Chemo-Immunotherapy. **2018**, 32, 125-133	2
807	Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic´ leukaemia treated with ibrutinib from 3 clinical trials. **2018**, 182, 504-512	32
806	Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. **2018**, 5, e563-e598	62
805	Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials. **2018**, 59, 2769-2781	12
804	A case of ibrutinib-associated aspergillosis presenting with central nervous system, myocardial, pulmonary, intramuscular, and subcutaneous abscesses. **2019**, 60, 559-561	8
803	Isavuconazole for the treatment of invasive fungal disease in patients receiving ibrutinib. **2019**, 60, 527-530	9
802	Cerebral aspergillosis in a patient on ibrutinib therapy-A predisposition not to overlook. **2019**, 25, 1486-1490	9
801	Ibrutinib for Treating Waldenstr ˆ m's Macroglobulinaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. **2019**, 37, 7-18	0

800	MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells. **2019**, 33, 403-414	30
799	The use of ibrutinib before and after allogeneic stem cell transplantation. **2019**, 7, 171-180	0
798	Novel therapeutics in hairy cell leukemia. **2019**, 12, 983-987	2
797	Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide. **2019**, 8, 16	8
796	Resolving PI3K-δ inhibitor resistance in CLL. **2019**, 134, 496-498	
795	The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. **2019**, 37, 392-400	25
794	Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. **2019**, 134, 851-859	151
793	In vitro metabolism of ibrutinib in rat, dog and human hepatocytes using liquid chromatography combined with diode-array detection and Q-Exactive Orbitrap tandem mass spectrometry. **2019**, 33, 1804-1815	5
792	A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia. **2019**, 60, 3461-3469	9
791	Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase. **2019**, 62, 7923-7940	108
790	Frontline therapies for untreated chronic lymphoid leukemia. **2019**, 8, 15	10
789	Real-world experience of ibrutinib therapy in relapsed chronic lymphocytic leukemia: results of a single-center retrospective analysis. **2019**, 10, 199-208	10
788	Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. **2019**, 6, e419-e428	41
787	Invasive fungal infections in the immunocompromised host: Mechanistic insights in an era of changing immunotherapeutics. **2019**, 57, S307-S317	18
786	Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study. **2019**, 37, 2722-2729	120
785	A one-two punch with VO KOs CLL. **2019**, 133, 2737-2738	
784	Current Applications for Overcoming Resistance to Targeted Therapies. **2019**,	1
783	Therapies to Overcome Multidrug-Resistant Receptors. **2019**, 131-159	1

782	Target engagement approaches for pharmacological evaluation in animal models. **2019**, 55, 9241-9250		1
781	Discovery and Development of a Series of Pyrazolo[3,4-]pyridazinone Compounds as the Novel Covalent Fibroblast Growth Factor Receptor Inhibitors by the Rational Drug Design. **2019**, 62, 7473-7488		14
780	Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia. **2019**, 185-190		1
779	Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. **2019**, 19, 715-722.e6		22
778	Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. **2019**, 94, 1266-1287		198
777	Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. *New England Journal of Medicine*, **2019**, 381, 432-443	59.2	322
776	A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk mutation in B-cell malignancies. **2019**, 176, 4491-4509		11
775	Ibrutinib-related atrial fibrillation: A single center Australian experience. **2019**, 15, e187-e190		4
774	Discovery of 4-Aminoquinoline-3-carboxamide Derivatives as Potent Reversible Bruton's Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis. **2019**, 62, 6561-6574		12
773	Chronic lymphocytic leukaemia: from genetics to treatment. **2019**, 16, 684-701		85
772	Prevalence of and mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study. **2019**, 134, 641-644		53
771	Discovery and Development of Non-Covalent, Reversible Bruton Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853). **2019**, 239-266		1
770	Ibrutinib-based therapy impaired neutrophils microbicidal activity in patients with chronic lymphocytic leukemia during the early phases of treatment. **2019**, 87, 106233		10
769	Severe Hepatotoxicity due to Ibrutinib with a Review of Published Cases. **2019**, 13, 357-363		5
768	CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. **2019**, 33, 2767-2778		34
767	Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. **2019**, 94, 1353-1363		152
766	Chronic Lymphocytic Leukemia. **2019**, 332-341		
765	Venous and arterial thrombosis in patients with haematological malignancy during treatment with ibrutinib. **2019**, 187, 399-402		6

764	Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?. **2019**, 9, 689	18
763	Comparison of Time to Next Treatment, Health Care Resource Utilization, and Costs in Patients with Chronic Lymphocytic Leukemia Initiated on Front-line Ibrutinib or Chemoimmunotherapy. **2019**, 19, 763-775.e2	8
762	Chemotherapie-freie Behandlung der CLL. **2019**, 40, 29-36	0
761	Cryoglobulinemic vasculitis with interruption of ibrutinib therapy for chronic lymphocytic leukemia (CLL). **2019**, 110, 751-755	0
760	Resistance to Targeted Therapies in Lymphomas. **2019**,	
759	Venetoclax for the Treatment of Chronic Lymphocytic Leukemia. **2019**, 14, 469-476	7
758	Cutting Edge: ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor-BTK Signaling Pathway. **2019**, 203, 2043-2048	15
757	[Chronic lymphocytic leukemia]. **2019**, 48, 807-815	6
756	Progress on small-molecule proteolysis-targeting chimeras. **2019**, 11, 2715-2734	6
755	Cardiovascular Toxicities Associated´ With Ibrutinib. **2019**, 74, 1667-1678	85
754	The Ibr-7 derivative of ibrutinib exhibits enhanced cytotoxicity against non-small cell lung cancer cells via targeting of mTORC1/S6 signaling. **2019**, 13, 946-958	6
753	Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL. **2019**, 15, 232-240	21
752	Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib. **2019**, 119, 397-406	21
751	The HDAC6-selective inhibitor is effective against non-Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma. **2019**, 58, 944-956	14
750	Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial. **2019**, 6, e100-e109	48
749	A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion. **2019**, 35, 283-296.e5	37
748	New roles for B cell receptor associated kinases: when the B cell is not the target. **2019**, 33, 576-587	14
747	Telomere length predicts for outcome to FCR chemotherapy in CLL. **2019**, 33, 1953-1963	10

746	Another step forward in the 20-year history of mutations in chronic lymphocytic leukemia. **2019**, 104, 219-221		5
745	Primary vitreoretinal lymphoma. **2019**, 33, 66-80		15
744	Development of BTK inhibitors for the treatment of B-cell malignancies. **2019**, 42, 171-181		28
743	The Role of Precision Medicine in the Diagnosis and Treatment of Patients with Rare Cancers. **2019**, 178, 81-108		2
742	Ibrutinib and Venetoclax for First-Line Treatment of CLL. *New England Journal of Medicine*, **2019**, 380, 2095-2103	59.2	256
741	SOHO State of the Art Updates and Next Questions: The Conundrum in Assessing the Therapy Response of Patients With Chronic Lymphocytic Leukemia. **2019**, 19, 321-325		1
740	Prognostic and Biologic Relevance of Clinically Applicable Long Noncoding RNA Profiling in Older Patients with Cytogenetically Normal Acute Myeloid Leukemia. **2019**, 18, 1451-1459		3
739	High incidence of atrial fibrillation in patients treated with ibrutinib. **2019**, 6, e001049		20
738	How to approach CLL in clinical practice. **2019**, 37 Suppl 1, 38-42		10
737	Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol. **2019**, 9, e026644		16
736	Linking aberrant chromatin features in chronic lymphocytic leukemia to transcription factor networks. **2019**, 15, e8339		20
735	Chronic Lymphocytic Leukemia: Who, How, and Where?. **2019**, 3-17		2
734	Characterization of Covalent Pyrazolopyrimidine-MKK7 Complexes and a Report on a Unique DFG-in/Leu-in Conformation of Mitogen-Activated Protein Kinase Kinase 7 (MKK7). **2019**, 62, 5541-5546		9
733	Simultaneous determination of evobrutinib and its metabolite evobrutinib-diol in dog plasma by liquid chromatography combined with electrospray ionization tandem mass spectrometry. **2019**, 33, e4575		
732	Structure-activity relationships of novel dithiocarbamates containing □,□-unsaturated ketone fragment as potent anticancer agents. **2019**, 28, 1027-1038		1
731	Ibrutinib induces chromatin reorganisation of chronic lymphocytic leukaemia cells. **2019**, 8, 32		5
730	Switch-like activation of Bruton's tyrosine kinase by membrane-mediated dimerization. **2019**, 116, 10798-10803		15
729	Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies. **2019**, 33, 2527-2530		51

728	Targeted delivery of ibrutinib to tumor-associated macrophages by sialic acid-stearic acid conjugate modified nanocomplexes for cancer immunotherapy. **2019**, 92, 184-195	38
727	Corrupted coordination of epigenetic modifications leads to diverging chromatin states and transcriptional heterogeneity in CLL. **2019**, 10, 1874	38
726	Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice. **2019**, 60, 2712-2719	28
725	IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia. **2019**, 134, 534-547	25
724	Structural and diffusion weighted MRI demonstrates responses to ibrutinib in a mouse model of follicular helper (Tfh) T-cell lymphoma. **2019**, 14, e0215765	5
723	Treating Older Patients with Chronic Lymphocytic Leukemia: A Personalized Approach. **2019**, 36, 841-851	
722	Major hemorrhage in chronic lymphocytic leukemia patients in the US Veterans Health Administration system in the pre-ibrutinib era: Incidence and risk factors. **2019**, 8, 2233-2240	7
721	Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma. **2019**, 7, 9	16
720	Structural mechanism for Bruton's tyrosine kinase activation at the cell membrane. **2019**, 116, 9390-9399	27
719	Chronic Lymphocytic Leukemia. **2019**,	
718	Targeting BTK in CLL: Beyond Ibrutinib. **2019**, 14, 197-205	65
717	Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018). **2019**, 29, 217-241	29
716	Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. **2019**, 133, 2031-2042	123
715	p66Shc deficiency in the Eμ-TCL1 mouse model of chronic lymphocytic leukemia enhances leukemogenesis by altering the chemokine receptor landscape. **2019**, 104, 2040-2052	9
714	Modulation of immune checkpoint molecule expression in mantle cell lymphoma. **2019**, 60, 2498-2507	10
713	Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions. **2019**, 104, 2292-2299	25
712	Ibrutinib for the treatment of chronic lymphocytic leukemia. **2019**, 12, 273-284	1
711	LMW-PTP targeting potentiates the effects of drugs used in chronic lymphocytic leukemia therapy. **2019**, 19, 67	5

710	Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in -Mutant Pancreatic and Colorectal Cancer. **2019**, 79, 2367-2378	31
709	Targeting CD20 takes the backseat in CLL. **2019**, 133, 1003-1004	0
708	[Kinase inhibitors in oncology : What is new?]. **2019**, 60, 540-544	
707	Relapsed/Refractory Chronic Lymphocytic Leukemia: Chemoimmunotherapy, Treatment until Progression with Mechanism-Driven Agents or Finite-Duration Therapy?. **2019**, 11, e2019024	3
706	Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. **2019**, 94, 710-725	83
705	B cell checkpoints in autoimmune rheumatic diseases. **2019**, 15, 303-315	31
704	Inhibiting Bruton's Tyrosine Kinase in CLL and Other B-Cell Malignancies. **2019**, 14, 125-138	24
703	Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan. **2019**, 110, 1686-1694	30
702	Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy. **2019**, 104, 2258-2264	16
701	Chronic lymphocytic leukemia (CLL) treatment: So many choices, such great options. **2019**, 125, 1432-1440	36
700	Targeting the MKK7-JNK (Mitogen-Activated Protein Kinase Kinase 7-c-Jun N-Terminal Kinase) Pathway with Covalent Inhibitors. **2019**, 62, 2843-2848	12
699	Targeting Thioredoxin Reductase by Ibrutinib Promotes Apoptosis of SMMC-7721 Cells. **2019**, 369, 212-222	10
698	Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia. **2019**, 12, 15	25
697	The Expanding Field of Secondary Antibody Deficiency: Causes, Diagnosis, and Management. **2019**, 10, 33	66
696	Management of adverse effects/toxicity of ibrutinib. **2019**, 136, 56-63	54
695	To the Editor, A multicenter, open-label, early access treatment protocol for ibrutinib in patients with relapsed or refractory mantle cell lymphoma. **2019**, 25, 1027-1030	1
694	Application of a sequential multiple assignment randomized trial (SMART) design in older patients with chronic lymphocytic leukemia. **2019**, 30, 542-550	4
693	Oral Anticancer Therapy: Management of Drug Interactions. **2019**, 15, 81-90	19

692	Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma. **2019**, 38, 86	14
691	Bruton's Tyrosine Kinase (BTK) Inhibitors as Sensitizing Agents for Cancer Chemotherapy. **2019**, 109-124	1
690	Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia. **2019**, 186, 184-188	5
689	Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis. **2019**, 185, 656-669	32
688	Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials. **2019**, 2019, 476-481	2
687	Sequential and combination treatments with novel agents in chronic lymphocytic leukemia. **2019**, 104, 2144-2154	19
686	Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. **2019**, 3, 1553-1562	101
685	Interleukin-2-inducible T-cell kinase inhibitors modify functional polarization of human peripheral T-cell lymphoma cells. **2019**, 3, 705-710	2
684	Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia. **2019**, 25, 7540-7553	11
683	Clonal dynamics in chronic lymphocytic leukemia. **2019**, 3, 3759-3769	7
682	Hypertension and incident cardiovascular events following ibrutinib initiation. **2019**, 134, 1919-1928	79
681	Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib. **2019**, 3, 447-460	24
680	Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. **2019**, 3, 1799-1807	61
679	Inhibition of EZH2 and immune signaling exerts synergistic antitumor effects in chronic lymphocytic leukemia. **2019**, 3, 1891-1896	4
678	Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin □IIb□3 in mice and humans. **2019**, 3, 4298-4311	27
677	Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials. **2019**, 134, 1796-1801	8
676	Phase I study of ibrutinib in Japanese patients with treatment-naˆ □e chronic lymphocytic leukemia/small lymphocytic lymphoma. **2019**, 59, 179-186	1
675	Targeted Therapy in Chronic Lymphocytic Leukemia. **2019**, 25, 378-385	14

674	Optimized Xenograft Protocol for Chronic Lymphocytic Leukemia Results in High Engraftment Efficiency for All CLL Subgroups. **2019**, 20,	4
673	BID and the □-bisabolol-triggered cell death program: converging on mitochondria and lysosomes. **2019**, 10, 889	6
672	Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia. **2019**, 11,	16
671	Cancer biomarkers for targeted therapy. **2019**, 7, 25	38
670	Long-Term Ibrutinib Therapy Reverses CD8 T Cell Exhaustion in B Cell Chronic Lymphocytic Leukaemia. **2019**, 10, 2832	23
669	Cost-effectiveness of New Targeted Agents in the Treatment of Chronic Lymphocytic Leukemia. **2019**, 25, 418-427	6
668	Emerging treatment options for patients with p53-pathway-deficient CLL. **2019**, 10, 2040620719891356	12
667	Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. **2019**, 9, 98	4
666	From Biology to Therapy: The CLL Success Story. **2019**, 3, e175	29
665	Bruton Tyrosine Kinase Inhibitors: Present and Future. **2019**, 25, 386-393	34
664	Relevance of Minimal Residual Disease in the Era of Targeted Agents. **2019**, 25, 410-417	4
663	In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment. **2019**, 11,	21
662	Arrhythmogenic Anticancer Drugs in Cardio-Oncology. **2019**, 37, 459-468	9
661	PharmaNews. **2019**, 42, 703-708	
660	Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?. **2019**, 3, e287	19
659	Cryptococcus neoformans infections in patients with lymphoproliferative neoplasms. **2019**, 60, 920-926	4
658	Loss of NFAT2 expression results in the acceleration of clonal evolution in chronic lymphocytic leukemia. **2019**, 105, 531-538	7
657	Deep targeted sequencing of in chronic lymphocytic leukemia: clinical impact at diagnosis and at time of treatment. **2019**, 104, 789-796	15

656	AKT/mTORC2 Inhibition Activates FOXO1 Function in CLL Cells Reducing B-Cell Receptor-Mediated Survival. **2019**, 25, 1574-1587	9
655	The applications of anti-CD20 antibodies to treat various B cells disorders. **2019**, 109, 2415-2426	19
654	The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia. **2019**, 33, 287-298	22
653	Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study. **2019**, 6, e38-e47	70
652	Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL). **2019**, 60, 1650-1655	18
651	CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia. **2019**, 33, 1161-1172	26
650	Dose-limiting stomatitis associated with ibrutinib therapy: a case series. **2019**, 185, 784-788	8
649	Integrated epigenomic and transcriptomic analysis reveals TP63 as a novel player in clinically aggressive chronic lymphocytic leukemia. **2019**, 144, 2695-2706	12
648	SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemia. **2019**, 184, 605-615	10
647	Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials. **2019**, 60, 1438-1446	11
646	Combinations or sequences of targeted agents in CLL: is the whole greater than the sum of its parts (Aristotle, 360 BC)?. **2019**, 133, 121-129	13
645	Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia. **2019**, 144, 2762-2773	8
644	First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013. **2019**, 104, 797-804	18
643	Enantioselective Addition of Pyrazole and Imidazole Heterocycles to Allenoates Catalyzed by Chiral Phosphine. **2019**, 131, 2880-2884	11
642	Dual inhibition of MEK1/2 and AKT by binimetinib and MK2206 induces apoptosis of chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment. **2019**, 60, 1632-1643	3
641	Neuropsychiatric lupus: new mechanistic insights and future treatment directions. **2019**, 15, 137-152	97
640	Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. **2019**, 6, e67-e78	95
639	Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study. **2019**, 60, 1972-1977	19

638	Acalabrutinib for adults with mantle cell lymphoma. **2019**, 12, 179-187	9
637	Enantioselective Addition of Pyrazole and Imidazole Heterocycles to Allenoates Catalyzed by Chiral Phosphine. **2019**, 58, 2854-2858	30
636	How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. **2019**, 133, 1298-1307	73
635	Chronic Lymphocytic Leukemia. **2019**,	
634	Assays on DNA Damage and Repair in CLL. **2019**, 1881, 153-163	1
633	Measurement of miRNAs in Chronic Lymphocytic Leukemia Patient Samples by Quantitative Reverse Transcription PCR. **2019**, 1881, 267-276	1
632	CUDC-907 blocks multiple pro-survival signals and abrogates microenvironment protection in CLL. **2019**, 23, 340-348	16
631	Ibrutinib Therapy Releases Leukemic Surface IgM from Antigen Drive in Chronic Lymphocytic Leukemia Patients. **2019**, 25, 2503-2512	14
630	Accumulation of DNA damage and alteration of the DNA damage response in monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. **2019**, 60, 795-804	6
629	Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. **2019**, 33, 969-980	70
628	Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation, proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model. **2019**, 8, e1512455	8
627	Palladium- and Rhodium-Catalyzed Dynamic Kinetic Resolution of Racemic Internal Allenes Towards Chiral Pyrazoles. **2019**, 58, 3378-3381	34
626	Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. **2019**, 184, 558-569	51
625	Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. **2019**, 133, 1011-1019	120
624	Personal Mutanomes Meet Modern Oncology Drug Discovery and Precision Health. **2019**, 71, 1-19	30
623	A rare colonic manifestation of chronic lymphocytic leukemia. **2019**, 60, 226-229	
622	Chimeric Antigen Receptor-T Cells for Leukemias in Adults: Methods, Data and Challenges. **2019**, 75-92	
621	Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction. **2019**, 30, 762-772	3

620	Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib. **2019**, 60, 1000-1005	11
619	Wide-range effects of the MALT-1 inhibitor Mi-2 in CLL cells results in apoptosis. **2019**, 60, 817-820	0
618	Direct inhibition of RAS: Quest for the Holy Grail?. **2019**, 54, 138-148	44
617	Cryptococcal infections in two patients receiving ibrutinib therapy for chronic lymphocytic leukemia. **2019**, 25, 710-714	12
616	Ibrutinib-associated sever skin toxicity: A case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia - Case report and literature review. **2020**, 26, 487-491	10
615	Ibrutinib induces multiple functional defects in the neutrophil response against. **2020**, 105, 478-489	28
614	Ibrutinib-associated oral ulcers. **2020**, 100, 104445	1
613	Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk. **2020**, 132, 97-109	4
612	Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL Registry. **2020**, 20, 174-183.e3	11
611	Itraconazole Increases Ibrutinib Exposure 10-Fold and Reduces Interindividual Variation-A Potentially Beneficial Drug-Drug Interaction. **2020**, 13, 345-351	10
610	Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo. **2020**, 151, 104512	6
609	Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects. **2020**, 85, 391-399	21
608	Using Informatics Tools to Identify Opportunities for Precision Medicine in Diffuse Large B-cell Lymphoma. **2020**, 20, 234-243.e10	
607	IGHV mutational status and outcome for patients with chronic lymphocytic leukemia upon treatment: a Danish nationwide population-based study. **2020**, 105, 1621-1629	12
606	Allogeneic Haploidentical Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide in Chronic Lymphocytic Leukemia. **2020**, 26, 502-508	5
605	Ibrutinib in the treatment of chronic lymphocytic leukemia: 5 years on. **2020**, 38, 129-136	10
604	Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia. **2020**, 55, 884-890	9
603	An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma. **2020**, 21, 29-38	3

602	Targeted cancer therapies (biologics). **2020**, 154-165.e4	
601	Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma. **2020**, 88, 106286	0
600	Discovery and Evaluation of Pyrazolo[3,4-]pyridazinone as a Potent and Orally Active Irreversible BTK Inhibitor. **2020**, 11, 1863-1868	4
599	Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors. **2020**, 28, 115236	6
598	Minimizing and managing treatment-associated complications in patients with chronic lymphocytic leukemia. **2020**, 13, 39-53	5
597	Reassessing the role of chemoimmunotherapy in chronic lymphocytic leukemia. **2020**, 13, 31-38	3
596	Chronic Lymphocytic Leukemia. **2020**, 1850-1871.e5	1
595	Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib. **2020**, 372, 331-338	10
594	Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL. **2019**, 21,	16
593	Overexpression of SH2-Containing Inositol Phosphatase Contributes to Chronic Lymphocytic Leukemia Survival. **2020**, 204, 360-374	5
592	Transformation to plasmablastic lymphoma in CLL upon ibrutinib treatment. **2020**, 13,	5
591	Genetic Loss of LCK Kinase Leads to Acceleration of Chronic Lymphocytic Leukemia. **2020**, 11, 1995	0
590	Ibrutinib in B-cell lymphoma: single fighter might be enough?. **2020**, 20, 467	4
589	IBL-202 is synergistic with venetoclax in CLL under in vitro conditions that mimic the tumor microenvironment. **2020**, 4, 5093-5106	0
588	Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia. **2020**, 36, 2009-2018	1
587	Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma. **2020**, 4, 4802-4811	12
586	Targeted Covalent Inhibition of Telomerase. **2020**, 15, 706-717	4
585	Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies. **2020**, 13, 871-883	5

584	Antihistamines are synergistic with Bruton's tyrosine kinase inhibiter ibrutinib mediated by lysosome disruption in chronic lymphocytic leukemia (CLL) cells. **2020**, 96, 106423		3
583	Pseudo-Richter transformation of chronic lymphocytic leukaemia/small lymphocytic lymphoma following ibrutinib interruption: a diagnostic pitfall. **2020**, 191, e22-e25		1
582	Next-Generation Bruton Tyrosine Kinase Inhibitors. **2020**, 38, 2937-2940		1
581	Current Treatment of Refractory/Relapsed Chronic Lymphocytic Leukemia: A Focus on Novel Drugs. **2021**, 144, 365-379		5
580	Highly Sensitive and Accurate Assessment of Minimal Residual Disease in Chronic Lymphocytic Leukemia Using the Novel CD160-ROR1 Assay. **2020**, 10, 597730		0
579	Standard treatment approaches for relapsed/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy. **2020**, 2020, 33-40		4
578	Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study. **2020**, 25, 100235		2
577	Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. **2020**, 61, 3188-3197		9
576	Innovative Therapeutic Approaches in Primary Cutaneous B Cell Lymphoma. **2020**, 10, 1163		4
575	Impact of amino acid substitution in the kinase domain of Bruton tyrosine kinase and its association with X-linked agammaglobulinemia. **2020**, 164, 2399-2408		11
574	Second cancer incidence in CLL patients receiving BTK inhibitors. **2020**, 34, 3197-3205		20
573	Treatment of Chronic Lymphocytic Leukemia. *New England Journal of Medicine*, **2020**, 383, 460-473	59.2	75
572	Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib. **2020**, 105, 646-654		15
571	Pyrazoline Hybrids as Promising Anticancer Agents: An Up-to-Date Overview. **2020**, 21,		22
570	Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma. **2020**, 19, 1105-1120		2
569	Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies. **2020**, 13, 103		26
568	Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naˆ Ïve and Relapsed or Refractory Chronic Lymphocytic Leukemia. **2020**, 38, 3626-3637		34
567	Discovery of Tricyclic Pyranochromenone as Novel Bruton's Tyrosine Kinase Inhibitors with in Vivo Antirheumatic Activity. **2020**, 21,		2

566	Inhibition of Bruton tyrosine kinase by acalabrutinib dampens lipopolysaccharide/galactosamine-induced hepatic damage. **2020**, 131, 110736	4
565	An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia. **2020**, 13, 1039-1046	1
564	Time to Next Treatment, Health Care Resource Utilization, and Costs Associated with Ibrutinib Use Among U.S. Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Retrospective Analysis. **2020**, 26, 1266-1275	1
563	Synergistic effect of ibrutinib and CD19 CAR-T cells on Raji cells in vivo and in vitro. **2020**, 111, 4051-4060	6
562	LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia. **2020**, 99, 2343-2349	2
561	Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. **2020**, 4, 3977-3989	30
560	Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib. **2020**, 61, 3422-3431	0
559	Bruton's tyrosine kinase inhibitors: a promising emerging treatment option for multiple sclerosis. **2020**, 25, 377-381	10
558	Phase I Oncology Drug Development. **2020**,	
557	Macrophage-Mediated Antibody Dependent Effector Function in Aggressive B-Cell Lymphoma Treatment is Enhanced by Ibrutinib via Inhibition of JAK2. **2020**, 12,	3
556	Systems biology drug screening identifies statins as enhancers of current therapies in chronic lymphocytic leukemia. **2020**, 10, 22153	2
555	Microenvironment Remodeling and Subsequent Clinical Implications in Diffuse Large B-Cell Histologic Variant of Richter Syndrome. **2020**, 11, 594841	6
554	Is there a real risk of bacterial infection in patients receiving targeted and biological therapies?. **2020**,	2
553	Zanubrutinib for the treatment of Waldenstr ̂ ﬁ n Macroglobulinemia. **2020**, 13, 1303-1310	0
552	Bruton's Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C3. **2020**, 12,	5
551	Therapeutic Targets in Chronic Lymphocytic Leukemia. **2020**, 12,	1
550	BTK Inhibitors in Cancer Patients with COVID-19: "The Winner Will be the One Who Controls That Chaos" (Napoleon Bonaparte). **2020**, 26, 3514-3516	29
549	Management of Ibrutinib Toxicities: a Practical Guide. **2020**, 15, 177-186	17

548	UGT2B17 modifies drug response in chronic lymphocytic leukaemia. **2020**, 123, 240-251	5
547	Low-dose Btk inhibitors selectively block platelet activation by CLEC-2. **2021**, 106, 208-219	20
546	Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations. **2020**, 63, 10726-10741	11
545	Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study. **2020**, 13, 48	41
544	Nonclinical Safety Assessment of Zanubrutinib: A Novel Irreversible BTK Inhibitor. **2020**, 39, 232-240	5
543	Mechanisms of B Cell Receptor Activation and Responses to B Cell Receptor Inhibitors in B Cell Malignancies. **2020**, 12,	15
542	Treatment algorithm for Japanese patients with chronic lymphocytic leukemia in the era of novel targeted therapies. **2020**, 60, 130-137	1
541	Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependencies. **2020**, 34, 2934-2950	5
540	Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell lymphomas. **2020**, 12,	27
539	Selinexor for advanced hematologic malignancies. **2020**, 61, 2335-2350	7
538	Novel mouse model resistant to irreversible BTK inhibitors: a tool identifying new therapeutic targets and side effects. **2020**, 4, 2439-2450	9
537	Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and Prospects. **2020**, 13, 4877-4892	8
536	The Evolution of Targeted Therapies in Chronic Lymphocytic Leukaemia. **2020**, 15, 343-349	1
535	Hepatitis B Virus Reactivation Potentiated by Biologics. **2020**, 34, 341-358	10
534	Efficacy of minimal residual disease driven immune-intervention after allogeneic hematopoietic stem cell transplantation for high-risk chronic lymphocytic leukemia: results of a prospective multicenter trial. **2021**, 106, 1867-1875	3
533	Genomic deregulation of PRMT5 supports growth and stress tolerance in chronic lymphocytic leukemia. **2020**, 10, 9775	2
532	Ibrutinib dose modifications in the management of CLL. **2020**, 13, 66	7
531	Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors. **2020**, 61, 2375-2382	10

530	Development of an application for management of drug holidays in perioperative periods. **2020**, 99, e20142	1
529	The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice. **2020**, 9, 3390-3399	19
528	Effects of ibrutinib on in vitro platelet aggregation in blood samples from healthy donors and donors with platelet dysfunction. **2020**, 25, 112-117	6
527	Ibrutinib-associated Arthralgias/Myalgias in Patients With Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes. **2020**, 20, 438-444.e1	14
526	Therapeutic drugs and drug delivery systems targeting stromal cells for cancer therapy: a review. **2020**, 28, 714-726	5
525	ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. **2020**, 16, 517-523	23
524	Advances in covalent kinase inhibitors. **2020**, 49, 2617-2687	69
523	Mitochondrial Respiration Correlates with Prognostic Markers in Chronic Lymphocytic Leukemia and Is Normalized by Ibrutinib Treatment. **2020**, 12,	6
522	Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia. **2021**, 106, 284-287	1
521	Resistance-Associated Mutations in Chronic Lymphocytic Leukemia Patients Treated With Novel Agents. **2020**, 10, 894	22
520	Ibrutinib is not an effective drug in primografts of TCF3-PBX1. **2020**, 13, 100817	
519	Cardiovascular Toxicities of Bruton's Tyrosine Kinase Inhibitors. **2020**, 21, 67	3
518	Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors. **2020**, 21, 799-812	21
517	In Human Visualization of Ibrutinib-Induced CLL Compartment Shift. **2020**, 8, 984-989	2
516	Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies. **2020**, 105, 2205-2217	21
515	T-Cell Dynamics in Chronic Lymphocytic Leukemia under Different Treatment Modalities. **2020**, 26, 4958-4969	9
514	Characterization of T-DM1-resistant breast cancer cells. **2020**, 8, e00617	3
513	Ibrutinib-induced polyneuropathy: A case report. **2020**, 26, 1501-1504	2

512	Revolution of Chronic Lymphocytic Leukemia Therapy: the Chemo-Free Treatment Paradigm. **2020**, 22, 16	14
511	Toxicities of novel therapies for hematologic malignancies. **2020**, 13, 241-257	2
510	Diffuse large B-cell lymphoma with low F-fluorodeoxyglucose avidity features silent B-cell receptor signaling. **2020**, 61, 1364-1371	1
509	Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia. **2020**, 34, 2342-2353	7
508	Role of Non-Coding RNAs in the Development of Targeted Therapy and Immunotherapy Approaches for Chronic Lymphocytic Leukemia. **2020**, 9,	7
507	An oral drug for chronic lymphocytic leukemia. **2020**, 33, 51-53	1
506	Celebrating 20 Years of IGHV Mutation Analysis in CLL. **2020**, 4, e334	10
505	Prevention of hepatitis B virus reactivation in patients with hematological malignancies and resolved hepatitis B virus infection: a systematic review and meta-analysis. **2020**, 21, 160-169	0
504	Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition. **2020**, 1864, 129531	39
503	Multifocal periungual granulation tissue related to ibrutinib therapy. **2020**, 6, 149-151	
502	Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL. **2020**, 11, 577	32
501	Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib. **2020**, 25, 25-35	10
500	Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. **2020**, 135, 1204-1213	81
499	Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?. **2020**, 111, 642-656	1
498	Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies. **2020**, 59, 1171-1183	7
497	Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors. **2020**, 4, 1458-1463	16
496	Inhibition of effector B cells by ibrutinib in systemic sclerosis. **2020**, 22, 66	14
495	Novel Targeted Therapies for Chronic Lymphocytic Leukemia in Elderly Patients: A Systematic Review. **2020**, 20, e414-e426	5

494	Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study. **2020**, 26, 3918-3927	69
493	CLL intraclonal fractions exhibit established and recently acquired patterns of DNA methylation. **2020**, 4, 893-905	1
492	Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months. **2020**, 4, 165-173	17
491	Chronic Lymphocytic Leukemia. **2021**, 11,	11
490	Novel pyrrolobenzodiazepine benzofused hybrid molecules inhibit NF-Ƀ activity and synergise with bortezomib and ibrutinib in hematological cancers. **2021**, 106, 958-967	1
489	Mathematical and Systems Medicine Approaches to Resistance Evolution and Prevention in Cancer. **2021**, 247-260	
488	Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial. **2021**, 106, 543-554	6
487	Efficacy of ibrutinib in late relapse chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation. **2021**, 39, 267-269	1
486	A multi-kinase inhibitor APG-2449 enhances the antitumor effect of ibrutinib in esophageal squamous cell carcinoma via EGFR/FAK pathway inhibition. **2021**, 183, 114318	5
485	Challenges and Opportunities in Cancer Drug Resistance. **2021**, 121, 3297-3351	66
484	Chemoproteomic Profiling of an Ibrutinib Analogue Reveals its Unexpected Role in DNA Damage Repair. **2021**, 22, 129-133	0
483	Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model. **2021**, 39, 576-585	36
482	Ibrutinib Suppresses Early Megakaryopoiesis but Enhances Proplatelet Formation. **2021**, 121, 192-205	3
481	Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia. **2021**, 137, 1117-1120	13
480	Four-Factor Score for Outcome of Ibrutinib Treatment in Chronic Lymphocytic Leukemia: Prognostic Model for Risk Group Definition. **2021**, 39, 551-553	3
479	Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma. **2021**, 21, 176-181	4
478	Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia. **2021**, 62, 716-721	0
477	Effects of CD20 antibodies and kinase inhibitors on B-cell receptor signalling and survival of chronic lymphocytic leukaemia cells. **2021**, 192, 333-342	2

476	Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies. **2021**, 193, 15-25	15
475	Snapshots and ensembles of BTK and cIAP1 protein degrader ternary complexes. **2021**, 17, 152-160	20
474	Engineering an Alcohol Dehydrogenase from Kluyveromyces polyspora for Efficient Synthesis of Ibrutinib Intermediate. **2021**,	2
473	U-RT1 - A new model for Richter transformation. **2021**, 23, 140-148	2
472	Novel antiplatelet strategies targeting GPVI, CLEC-2 and tyrosine kinases. **2021**, 32, 29-41	5
471	Severe ulcerative gastrointestinal toxicity following ibrutinib therapy: two case studies. **2021**, 62, 984-987	0
470	Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P-gp and BCRP. **2021**, 87, 2926-2936	7
469	Strategies for Targeting the NLRP3 Inflammasome in the Clinical and Preclinical Space. **2021**, 64, 101-122	25
468	Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances. **2021**, 35, 312-332	52
467	SLAMF receptors negatively regulate B cell receptor signaling in chronic lymphocytic leukemia via recruitment of prohibitin-2. **2021**, 35, 1073-1086	3
466	Target Validation Prosecuting the Target. **2021**,	
465	Der Stand der Therapie bei der refrakt ̂ en/rezidivierenden chronischen lymphatischen Leuk ̂ hie: Neuartige Wirkstoffe im Fokus. **2021**, 8, 59-69	
464	Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort. **2021**, 100, 987-993	13
463	Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia. **2021**, 62, 1066-1076	2
462	Early Transformation to Classic Hodgkin Lymphoma in a Chemotherapy-na ̂ ve Chronic Lymphocytic Leukemia Patient upon Initial Treatment with Ibrutinib. **2021**, 60, 3305-3308	0
461	Follicular Lymphoma-associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation. **2021**, 27, 2301-2313	7
460	Recent advances in activity-based probes (ABPs) and affinity-based probes (ABPs) for profiling of enzymes. **2021**, 12, 8288-8310	18
459	Telomere Dysfunction in Chronic Lymphocytic Leukemia. **2020**, 10, 612665	2

458	Changing Definition of Immunosuppression: Targeted Therapies and Resulting Emerging Infections and Their Prevention. **2021**, 25-41	
457	Overcoming resistance to targeted therapies in chronic lymphocytic leukemia. **2021**, 5, 334-343	9
456	Development and clinical use of an application for management of drug holidays in perioperative periods. **2021**, 32, 339-348	
455	Epigenetic targeting of Waldenstr^ Ĥ macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition. **2021**, 13, 129-144	3
454	The Calcitriol/Vitamin D Receptor System Regulates Key Immune Signaling Pathways in Chronic Lymphocytic Leukemia. **2021**, 13,	2
453	Single-Cell RNA-Seq Reveals LGALS1 and LAG3 as Novel Drivers of Ibrutinib Resistance in Chronic Lymphocytic Leukemia.	
452	Impact of Adherence to Ibrutinib on Clinical Outcomes in Real-World Patients With Chronic Lymphocytic Leukemia. **2021**, 12, 20-28	
451	Targeting the NLRP3 Inflammasome via BTK. **2021**, 9, 630479	12
450	Richter Syndrome. **2021**, 23, 26	7
449	Characterization of ibrutinib as a non-covalent inhibitor of SRC-family kinases. **2021**, 34, 127757	3
448	Ibrutinib-Induced Skin Rash. **2021**, 38, 81-83	1
447	Outcomes in chronic lymphocytic leukemia patients on novel agents in the US Veterans Health Administration System. **2021**, 62, 1664-1673	2
446	BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib. **2021**, 35, 1317-1329	9
445	Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication. **2021**, 11, 39	4
444	Therapeutic Options for Patients with TP53 Deficient Chronic Lymphocytic Leukemia: Narrative Review. **2021**, 13, 1459-1476	0
443	Prognostic factors and effectiveness of the first-line therapy for chronic lymphocytic leukemia: results of 10-year follow-up. **2021**, 27, 80-96	1
442	Oncotherapeutic Protein Kinase Inhibitors Associated With Pro-Arrhythmic Liability. **2021**, 3, 88-97	4
441	Novel Agents in Chronic Lymphocytic Leukemia: New Combination Therapies and Strategies to Overcome Resistance. **2021**, 13,	9

440	FoxO1-GAB1 axis regulates homing capacity and tonic AKT activity in chronic lymphocytic leukemia. **2021**, 138, 758-772	3
439	Incorporating Novel Targeted and Immunotherapeutic Agents in Treatment of B-Cell Lymphomas. **2021**, 41, 1-18	
438	Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. **2021**, 106, 2364-2373	21
437	Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients. **2021**,	1
436	Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. **2021**, 397, 892-901	81
435	The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action. **2021**, 11, 57	5
434	Risk of bleeding complications and atrial fibrillation associated with ibrutinib treatment: A systematic review and meta-analysis. **2021**, 159, 103238	8
433	Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects. **2021**, 9, 630942	37
432	Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton's Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia. **2021**, 15, 919-926	4
431	Population Pharmacokinetics of Ibrutinib in Healthy Adults. **2021**, 46, 405-413	
430	Population PK-PD Modeling of Circulating Lymphocyte Dynamics in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment. **2021**, 110, 220-228	1
429	Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group. **2021**, 39, 326-335	3
428	Of Lymph Nodes and CLL Cells: Deciphering the Role of CCR7 in the Pathogenesis of CLL and Understanding Its Potential as Therapeutic Target. **2021**, 12, 662866	4
427	Oral PI3K-δ Inhibitor for the Management of People with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Narrative Review on Duvelisib. **2021**, 14, 2109-2119	3
426	The Right Dose: From Phase I to Clinical Practice. **2021**, 41, 92-106	1
425	Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients. **2021**, 35, 3287-3290	
424	Ibrutinib combinations in CLL therapy: scientific rationale and clinical results. **2021**, 11, 79	8
423	A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20-Yet Progress Continues. **2021**, 18, 1602-1622	1

422	The structure of CLEC-2: mechanisms of dimerization and higher-order clustering. **2021**, 32, 733-743	6
421	Phase I, first-in-human trial of Bruton's tyrosine kinase inhibitor M7583 in patients with B-cell malignancies. **2021**, 62, 2392-2399	0
420	Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. **2021**, 35, 3201-3211	4
419	Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922). **2021**, 31, 162-172	3
418	The future of laboratory testing in chronic lymphocytic leukaemia. **2021**, 53, 377-384	0
417	Experimental and Density Functional Theory Characteristics of Ibrutinib, a Bruton Kinase Inhibitor Approved for Leukemia Treatment. **2021**, 2021, 1-8	0
416	Impact of COVID-19 in patients with lymphoid malignancies. **2021**, 10, 97-110	6
415	Current Treatment Options in CLL. **2021**, 13,	4
414	B-cell targeted therapies in pemphigus. **2021**, 156,	0
413	Asymptomatic Purpuric Eruption on the Scalp of a Middle-aged Man. **2021**, 7, 771-772	
412	Assessment of the effects of Syk and BTK inhibitors on GPVI-mediated platelet signaling and function. **2021**, 320, C902-C915	7
411	Diagnosis and Individualized Treatment of Secondary Central Nervous System Lymphoma: A Case Report. **2021**, 14, 3167-3175	0
410	Screening and monitoring of the BTK mutation in a real-world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy. **2021**, 194, 355-364	2
409	Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome. **2021**, 11, 86	4
408	Frontline Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Targeted Therapy vs. Chemoimmunotherapy. **2021**, 16, 325-335	0
407	Bruton's Tyrosine Kinase Targeting in Multiple Myeloma. **2021**, 22,	4
406	Chronic lymphocytic leukemia and the skin: implications for the dermatologist. **2021**,	0
405	Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. **2021**, 6, 201	103

404	Distinct BTK inhibitors differentially induce apoptosis but similarly suppress chemotaxis and lipid accumulation in mantle cell lymphoma. **2021**, 21, 732	0
403	New drugs and pharmacological interactions in real life. **2021**, 39 Suppl 1, 78-82	
402	Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors. **2021**, 128, 1973-1987	1
401	Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as Potential Repurposed Drugs against COVID-19. **2021**, 22,	7
400	A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO-idel). **2021**, 194, 69-77	4
399	Ibrutinib: another string to its bow. **2021**, 137, 3461-3462	1
398	TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target. **2021**, 137, 3064-3078	2
397	Intrinsic OXPHOS limitations underlie cellular bioenergetics in leukemia. **2021**, 10,	7
396	Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited-duration therapy. **2021**, 138, 836-846	6
395	Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma. **2021**, 21, 158-170	2
394	Targeted PI3K/AKT-hyperactivation induces cell death in chronic lymphocytic leukemia. **2021**, 12, 3526	9
393	On the road to optimized BTK inhibition in CLL. **2021**, 137, 3313-3314	1
392	Phase 2 study of ibrutinib in classic and variant hairy cell leukemia. **2021**, 137, 3473-3483	15
391	Acalabrutinib in treatment-naive chronic lymphocytic leukemia. **2021**, 137, 3327-3338	18
390	Resistance Mutations to BTK Inhibitors Originate From the NF-Β but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway. **2021**, 12, 689472	6
389	Activation of Protein Tyrosine Phosphatase Receptor Type □ Suppresses Mechanisms of Adhesion and Survival in Chronic Lymphocytic Leukemia Cells. **2021**, 207, 671-684	2
388	Targeting Bruton's Tyrosine Kinase in CLL. **2021**, 12, 687458	11
387	Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia. **2021**, 13,	0

386	Towards Control Of Chronic Lymphocytic Leukemia With Targeted Agents. **2021**, 39,	1
385	Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. **2021**, 35, 3059-3072	6
384	CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities. **2021**, 12, 693016	7
383	Autoimmune Cytopenia in CLL: Prognosis and Management in the Era of Targeted Therapies. **2021**, 27, 286-296	0
382	Secondary Hypogammaglobulinemia in Patients with Chronic Lymphocytic Leukemia Receiving Ibrutinib Therapy.. **2022**, 38, 282-289	0
381	MCIR1: A patient-derived mantle cell lymphoma line for discovering new treatments for ibrutinib resistance. **2021**, 107, 458-465	0
380	Risk Factors for Cost-Related Delays to Medical Care Among Lymphoma Patients: A 22-Year Analysis of a Nationally Representative Sample. **2021**, 21, e619-e625	4
379	Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective. **2021**, 22,	9
378	Possible Therapeutic Strategy Involving the Purine Synthesis Pathway Regulated by ITK in Tongue Squamous Cell Carcinoma. **2021**, 13,	1
377	Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenstr ˆ h macroglobulinemia. **2021**, 138, 1535-1539	7
376	A patent review of MALT1 inhibitors (2013-present). **2021**, 31, 1079-1096	1
375	BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects. **2021**, 12, 686768	4
374	Bruton's Tyrosine Kinase and Its Isoforms in Cancer. **2021**, 9, 668996	6
373	Temporary cessation of ibrutinib results in reduced grade 3-4 infections and durable remissionsInterim analysis of an on-off-repeat Phase 1b/2 study in patients with chronic lymphocytic leukemia. **2021**, 2, 525-529	0
372	Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors. **2021**, 12, 694853	9
371	Can Immunocompetence Be Restored in Chronic Lymphocytic Leukemia?. **2021**, 35, 827-845	
370	Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors. **2021**, 35, 793-806	
369	Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. **2021**, 7, 1213-1219	17

368	Richter transformation heralded by EBV reactivation during ibrutinib therapy for chronic lymphocytic leukemia. **2021**, 62, 3051-3053	1
367	Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data. **2021**, 38, 273-285	
366	Severe Lymphocytosis in a Case of Diffuse Large B-Cell Lymphoma Treated by Ibrutinib. **2021**, 38, 337-338	0
365	Immunomodulatory Drugs for the Treatment of B Cell Malignancies. **2021**, 22,	1
364	The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia: TP53 Disruption, Richter, and Beyond. **2021**, 35, 739-759	1
363	Extrinsic interactions in the microenvironment in vivo activate an antiapoptotic multidrug-resistant phenotype in CLL. **2021**, 5, 3497-3510	2
362	Bruton Tyrosine Kinase Inhibition and Its Role as an Emerging Treatment in Pemphigus. **2021**, 8, 708071	1
361	Incidence and associated risk factors for invasive fungal infections and other serious infections in patients on ibrutinib. **2021**, 27, 1700-1705	6
360	Non-Covalent BTK Inhibitors-The New BTKids on the Block for B-Cell Malignancies. **2021**, 11,	8
359	Genomics of Resistance to Targeted Therapies. **2021**, 35, 715-724	
358	Drug interaction (51. New oral anticancer drugs in hematological malignancies and drug interactions). **2021**, 133, 120-126	
357	Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions. **2021**, 14, 819-830	4
356	Bruton's tyrosine kinase inhibition induces rewiring of proximal and distal B-cell receptor signaling in mice. **2021**, 51, 2251-2265	2
355	First-Line Therapy for Chronic Lymphocytic Leukemia: Bruton Tyrosine Kinase or BCL2 or Both?. **2021**, 35, 725-738	1
354	Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Beyond Ibrutinib. **2021**, 35, 761-773	2
353	Acalabrutinib in the treatment of chronic lymphocytic leukemia: a review of recent evidence. **2021**, 23, 332-338	
352	Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome. **2021**, 5, 3528-3539	6
351	The road to chemotherapy-free treatment in chronic lymphocytic leukaemia. **2021**, 33, 670-680	0

350	Bruton's Tyrosine Kinase Inhibitors: A New Generation of Promising Agents for Multiple Sclerosis Therapy. **2021**, 10,	6
349	Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non-Hodgkin Lymphoma. **2021**, 27, 6591-6601	3
348	Ibrutinib in Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Lower Risk of Hepatitis B Virus Reactivation. **2021**, 1-9	1
347	The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphoma. **2021**, 24, 102931	1
346	BTK inhibitors as potential therapies for multiple sclerosis. **2021**, 20, 689-691	1
345	BTK operates a phospho-tyrosine switch to regulate NLRP3 inflammasome activity. **2021**, 218,	9
344	Modeling the Binding and Conformational Energetics of a Targeted Covalent Inhibitor to Bruton's Tyrosine Kinase. **2021**, 61, 5234-5242	3
343	Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib. **2021**, 14, 1329-1344	4
342	Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. **2021**,	5
341	Revisiting Richter transformation in the era of novel CLL agents. **2021**, 49, 100824	4
340	Case Presentation Relapse After Frontline BTKi Therapy in Patients with CLL: Options and Consideration. **2021**, 21, S40-S42	
339	Repurposing of gastric cancer drugs against COVID-19. **2021**, 137, 104826	2
338	Intrinsic 5-lipoxygenase activity regulates migration and adherence of mantle cell lymphoma cells. **2021**, 156, 106575	1
337	Synthesis, biological evaluation and X-ray crystallographic analysis of novel (E)-2-cyano-3-(het)arylacrylamides as potential anticancer agents. **2021**, 1244, 130944	6
336	Alternative strategies for optimizing treatment of chronic lymphocytic leukemia with complex clonal architecture. **2021**, 110, 106663	
335	The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Impairs the Vascular Development of Zebrafish Larvae. **2020**, 11, 625498	1
334	A Rare Side Effect of Ibrutinib: Tumor Lysis Syndrome. **2021**, 36, 176-179	0
333	The evolving role of Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia. **2021**, 12, 20406207219889588	9

332	Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies. **2021**, 106, 2022-2025	4
331	Introduction to Kinase Antitargets. 329-364	1
330	Targeted Therapeutics for Lymphoma: Using Biology to Inform Treatment. **2019**, 343-360	1
329	Dasatinib. **2014**, 201, 27-65	46
328	STAT3 mediates C6-ceramide-induced cell death in chronic lymphocytic leukemia. **2017**, 2, 17051	7
327	Switch-like activation of Bruton tyrosine kinase by membrane-mediated dimerization.	2
326	Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib drug response in chronic lymphocytic leukemia.	2
325	Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity. **2019**, 4,	10
324	LC-FACSeq is a method for detecting rare clones in leukemia. **2020**, 5,	1
323	Inhibition of ER stress-associated IRE-1/XBP-1 pathway reduces leukemic cell survival. **2014**, 124, 2585-98	119
322	Drug-perturbation-based stratification of blood cancer. **2018**, 128, 427-445	72
321	Treatment of relapsed chronic lymphocytic leukemia after venetoclax. **2020**, 2020, 18-23	3
320	Recent therapeutic advances in chronic lymphocytic leukemia. **2017**, 6, 1924	12
319	Advances in treating chronic lymphocytic leukemia. **2014**, 6, 65	12
318	Insulin growth factor 1 receptor expression is associated with NOTCH1 mutation, trisomy 12 and aggressive clinical course in chronic lymphocytic leukaemia. **2015**, 10, e0118801	12
317	Spleen Tyrosine Kinase Is Involved in the CD38 Signal Transduction Pathway in Chronic Lymphocytic Leukemia. **2016**, 11, e0169159	4
316	Targeting Interleukin-2-Inducible T-cell Kinase (ITK) in T-Cell Related Diseases. **2014**, 2, 1-11	9
315	New targeted therapies for indolent B-cell malignancies in older patients. **2015**, e365-74	0

314	Efficacy of Ibrutinib-Based Regimen in Chronic Lymphocytic Leukemia: A Systematic Review. **2019**, 8, 1-10	5
313	Oncogenic Signaling Pathways and Pathway-Based Therapeutic Biomarkers in Lymphoid Malignancies. **2017**, 22, 527-557	1
312	Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL. **2016**, 7, 68833-68841	47
311	Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation. **2016**, 7, 69760-69769	33
310	Specificity and biologic activities of novel anti-membrane IgM antibodies. **2016**, 7, 74701-74723	1
309	Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside. **2017**, 8, 7201-7207	23
308	Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells. **2017**, 8, 742-756	13
307	Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment. **2017**, 8, 12953-12967	26
306	A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor. **2014**, 5, 908-15	49
305	Using high-sensitivity sequencing for the detection of mutations in BTK and PLC2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors. **2017**, 8, 17936-17944	20
304	Changes in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number. **2017**, 8, 34661-34669	25
303	BTK suppresses myeloma cellular senescence through activating AKT/P27/Rb signaling. **2017**, 8, 56858-56867	4
302	Cell lines generated from a chronic lymphocytic leukemia mouse model exhibit constitutive Btk and Akt signaling. **2017**, 8, 71981-71995	14
301	Translocation of heme oxygenase-1 contributes to imatinib resistance in chronic myelogenous leukemia. **2017**, 8, 67406-67421	7
300	Antibody-assisted target identification reveals afatinib, an EGFR covalent inhibitor, down-regulating ribonucleotide reductase. **2018**, 9, 21512-21529	7
299	Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma. **2018**, 9, 24731-24736	12
298	A novel high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia. **2018**, 9, 26019-26031	5
297	Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemia. **2018**, 9, 34398-34412	8

296	Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. **2019**, 10, 3827-3830	2
295	CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21. **2015**, 6, 12048-60	15
294	The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells. **2015**, 6, 19102-17	13
293	RPPA-based protein profiling reveals eIF4G overexpression and 4E-BP1 serine 65 phosphorylation as molecular events that correspond with a pro-survival phenotype in chronic lymphocytic leukemia. **2015**, 6, 14632-45	16
292	miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the E´ μ-TCL1 mouse model. **2015**, 6, 19807-18	22
291	Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells. **2015**, 6, 31313-22	32
290	Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma. **2015**, 6, 42232-42	20
289	Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib. **2016**, 7, 4598-610	34
288	Ibrutinib. **2015**, 38, 178-80	3
287	Promises and pitfalls of targeted agents in chronic lymphocytic leukemia.. **2020**, 3, 415-444	2
286	Ibrutinib in the Treatment of Refractory Chronic Lymphocytic Leukemia. **2017**, 10, 271-281	1
285	Turning to Computer-aided Drug Design in the Treatment of Diffuse Large B-cell Lymphoma: Has it been Helpful?. **2019**, 19, 1325-1339	1
284	Copanlisib: Novel PI3K Inhibitor for the Treatment of Lymphoma. **2020**, 20, 1158-1172	3
283	Intratumoral spatial heterogeneity of BTK kinomic activity dictates distinct therapeutic response within a single glioblastoma tumor. **2019**, 1-12	4
282	Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration. **2021**, 106, 2845-2852	7
281	Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors. **2020**, 1, 131-152	9
280	[Ibrutinib inhibits mesenchymal stem cells-mediated drug resistance in diffuse large B-cell lymphoma]. **2017**, 38, 1036-1042	3
279	[The guidelines for diagnosis and treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma in China (2018 edition)]. **2018**, 39, 353-358	2

278	MicroRNA-425 inhibits proliferation of chronic lymphocytic leukaemia cells through regulation of the Bruton's tyrosine kinase/phospholipase C signalling pathway. **2020**, 20, 1169-1175	2
277	Chronic lymphocytic leukemia: a clinical review including Korean cohorts. **2016**, 31, 433-43	6
276	Measurable residual disease in the treatment of chronic lymphocytic leukemia. **2020**, 60, 138-145	0
275	Pathogenesis of chronic lymphocytic leukemia and the development of novel therapeutic strategies. **2020**, 60, 146-158	2
274	Efficacy and Safety of Ibrutinib in Indian Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: Cases from a Named Patient Program. **2017**, 38, 508-515	4
273	Recent advances in chronic lymphocytic leukemia therapy. **2020**, 55, S72-S82	3
272	Ibrutinib: Implications for Use in the Treatment of Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia. **2015**, 6, 420-31	3
271	Chronic Lymphocytic Leukemia (CLL): Biology and Therapy. **2021**, 181, 133-149	
270	Bruton's Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease. **2021**, 81, 1605-1626	5
269	Targeting Notch to Maximize Chemotherapeutic Benefits: Rationale, Advanced Strategies, and Future Perspectives. **2021**, 13,	3
268	Evaluation of vecabrutinib as a model for non-covalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia. **2021**,	3
267	Precision diagnostics in lymphomas - Recent developments and future directions. **2021**,	0
266	Small Molecule Kinase Inhibitor Drugs (1995-2021): Medical Indication, Pharmacology, and Synthesis. **2021**,	11
265	BTK Inhibitors in Chronic Lymphocytic Leukemia. **2021**, 16, 422-432	1
264	Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. **2021**, 96, 1679-1705	19
263	Ibrutinib's off-target mechanism: cause for dose optimization. **2021**, 1-3	1
262	The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma. **2021**, 39, 605-615	1
261	Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. **2021**, 39, 3853-3865	17

260 Nanomedicines in B cell-targeting therapies. **2021**, 137, 1-1 1

259 Lymphoma, Non-Hodgkin□?. **2014**,

258 Molecular targeted therapies in leukemia. **2014**, 126, 49-54

257 Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia. **2014**, 5, 348-54

256 Apoptosis Pathways in Chronic Lymphocytic Leukemia: Role of the Microenvironment and Therapeutic Strategies. **2015**, 73-98

255 Lenalidomide following fludarabine and rituximab in previously untreated CLL. **2015**, 3, 2

254 Novel Agents in the Treatment of Chronic Lymphocytic Leukemia. **2015**, 88, 258

253 E28 Literaturhinweise und Internetadressen. **2015**, e1-e79

252 Chronic lymphocytic leukemia/small lymphocytic lymphoma. 133-144

251 Leukaemia. 427-448

250 Molecular Targeted Anticancer Drugs. **2016**, 175-238

249 Encyclopedia of Signaling Molecules. **2016**, 1-10

248 Chronic Lymphocytic Leukemia: Prognostic Significance of Minimal Residual Disease and Potential of Modern Methods of Its Diagnosis and Therapy (Literature Review). **2016**, 9, 191-198

247 Treatment of B-cell lymphomas. **2016**, 45-57

246 Ibrutinib in hematoonkology. **2016**, 30, 8-14 0

245 Small B-cell lymphocytic lymphoma and chronic lymphocytic leukemia. **2017**, 47-73

244 Indolente (niedrig maligne) Non-Hodgkin-Lymphome. **2017**, 437-484

243 Leukaemia. 427-448

224	Clonal dynamics in chronic lymphocytic leukemia. **2019**, 2019, 466-475	
223	Changing Definition of Immunosuppression: Targeted Therapies and Resulting Emerging Infections and Their Prevention. **2020**, 1-17	
222	Ibrutinib blocks YAP1 activation and reverses BRAFi resistance in melanoma cells.	0
221	Macrophage-mediated antibody dependent effector function in aggressive B-cell lymphoma treatment is enhanced by Ibrutinib via inhibition of JAK2.	
220	ARQ531: the therapy that targets multiple pathways in acute myeloid leukemia. **2020**, 105, 2350-2352	
219	HDAC1 regulates the chromatin landscape to establish transcriptional dependencies in chronic lymphocytic leukemia.	0
218	Treatment strategies for a rapidly evolving landscape in chronic lymphocytic leukemia management. **2021**,	0
217	Targeting of HSP70/HSF1 Axis Abrogates In Vitro Ibrutinib-Resistance in Chronic Lymphocytic Leukemia. **2021**, 13,	2
216	The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View. **2021**, 13, 923-935	4
215	Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study. **2021**, 8, e912-e921	8
214	Tumorzellspezifisches Targeting von Ibrutinib: Einf□hrung von elektrostatischen Antik□per-Inhibitor-Konjugaten (AiCs).	
213	Safety and efficacy analysis of ibrutinib in 32 patients with CLL and various B-cell lymphomas: real-world data from a single-center study in Turkey. **2020**, 55, 206-212	3
212	MODERN APPROACHES TO TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA. **2020**, 19, 106-118	
211	Tumor lysis syndrome in chronic lymphocytic leukemia: conventional treatment versus novel agents: A protocol for systematic review and meta-analysis. **2020**, 99, e23632	0
210	Graft Versus Host Disease (GHVD) in Critically Ill Oncologic Patients. **2020**, 249-265	
209	Clinical Efficacy of Ibrutinib Monotherapy and CHOP in the Treatment of Chronic Lymphocytic Leukemia. **2020**, 10, 2819-2826	
208	The Paradigm of Early Phase Studies in Hematological Malignancies. **2020**, 297-311	
207	Ibrutinib skin toxicities: Report of two cases. **2021**,	0

206	Cooperative miRNA-dependent PTEN regulation drives resistance to BTK inhibition in B-cell lymphoid malignancies. **2021**, 12, 1061	4
205	Ibrutinib blocks YAP1 activation and reverses BRAFi resistance in melanoma cells. **2021**,	0
204	Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice. **2021**, 11, 720704	8
203	Tumor-Cell-Specific Targeting of Ibrutinib: Introducing Electrostatic Antibody-Inhibitor Conjugates (AiCs). **2021**,	0
202	Endothelial dysfunction in patients with lymphoproliferative disorders and its changes in the course of polychemotherapy. **2020**, 9,	2
201	Risk of Bleeding Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. **2020**, 11, 580622	3
200	Structural basis for producing selective MAP2K7 inhibitors. **2020**, 30, 127546	0
199	Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab. **2020**, 106, 1500-1503	1
198	Ibrutinib (imbruvica): a novel targeted therapy for chronic lymphocytic leukemia. **2014**, 39, 483-519	29
197	Know the enemy as well as the weapons in hand: the aberrant death pathways and therapeutic agents in chronic lymphocytic leukemia. **2015**, 5, 2361-75	6
196	Imbruvica (Ibrutinib), First-in-Class Bruton's Tyrosine Kinase Inhibitor, Receives Expanded Indications for Patients with Relapsed Chronic Lymphocytic Leukemia. **2015**, 8, 66-9	2
195	CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas. **2016**, 6, 403-24	18
194	New Pharmacotherapies in Chronic Lymphocytic Leukemia. **2017**, 42, 106-115	1
193	Risk-Stratified Treatment in Chronic Lymphocytic Leukemia. **2016**, 7, 314-317	
192	Risk Assessment and Risk-Adapted Treatment Selection: A Case-Based Approach for Chronic Lymphocytic Leukemia. **2017**, 8, 502-520	1
191	New Treatments for Chronic Lymphocytic Leukemia. **2015**, 32, 54S-55S	1
190	[Ibrutinib treatment for 2 cases of relapsed/refractory autoimmune hemolytic anemia: a pilot study]. **2020**, 41, 412-416	
189	[How we diagnose and treat chronic lymphocytic leukemia]. **2018**, 39, 529-532	0

188	[Venetoclax combined with rituximab in the treatment of ibrutinib-resistant patient with chronic lymphocytic leukemia: a case report and literature reviews]. **2019**, 40, 700-702	
187	[Application of ibrutinib in primary central nervous system lymphoma]. **2020**, 41, 348-350	
186	Atrial Fibrillation and Bleeding in Patients With Chronic Lymphocytic Leukemia Treated with Ibrutinib in the Veterans Health Administration. **2020**, 37, S44-S49	
185	[Clinical value of PET/CT in the diagnosis of Richter syndrome]. **2020**, 41, 689-693	
184	Protein kinase C-□-dependent changes in the glucose metabolism of bone marrow stromal cells of chronic lymphocytic leukemia. **2021**, 39, 819-830	0
183	Pharmacology and pharmacovigilance of protein kinase inhibitors.. **2021**,	1
182	Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial. **2021**,	1
181	Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past is Prologue" (Shakespeare). **2021**,	2
180	B-cell receptor isotypes differentially associate with cell signaling, kinetics, and outcome in chronic lymphocytic leukemia. **2021**,	1
179	BTK-inhibitor drug covalent binding to lysine in human serum albumin using LC-MS/MS.. **2021**, 42, 100433	1
178	Btk Supports Autoreactive B Cell Development and Protects against Apoptosis but Is Expendable for Antigen Presentation. **2021**,	1
177	Outcomes of patients diagnosed with chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation: Results from a tertiary care center. **2021**,	
176	Discovery of pyrido[3,4-b]indol-1-one derivatives as novel non-covalent Bruton's tyrosine kinase (BTK) inhibitors.. **2021**, 119, 105541	1
175	Advance in the Treatment with Molecular Targeted Drugs for Malignant Lymphoma and Chronic Lymphocytic Leukemia. **2020**, 109, 2183-2190	
174	Bone Marrow Changes Following Therapy and Immunosuppression. **2020**, 314-339	0
173	Towards precision medicine in lymphoid malignancies. **2021**,	1
172	Some important inhibitors and mechanisms of rheumatoid arthritis.. **2021**,	1
171	Biological and Clinical Insight from Analysis of the Tumor B-Cell Receptor Structure and Function in Chronic Lymphocytic Leukemia.. **2022**, 14,	1

170	CLL update 2022: A continuing evolution in care.. **2022**, 100930	1
169	Targeted Therapy in Leukaemia, Lymphoma and Myeloma.. **2022**, 12,	0
168	Ibrutinib Combined With Low-Dose HDAC Inhibitor Chidamide Synergistically Enhances the Anti-Tumor Effect in B-Cell Lymphoma.	
167	Evolution of TP53 abnormalities during CLL disease course is associated with telomere length changes.. **2022**, 22, 137	1
166	Acalabrutinib and its use in the treatment of chronic lymphocytic leukemia.. **2022**,	1
165	Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features.. **2021**, 17, 69	9
164	Preparation of chiral aryl alcohols: a controllable enzymatic strategy via light-driven NAD(P)H regeneration. **2022**, 46, 6274-6282	0
163	Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.. **2022**,	10
162	Successful treatment of refractory pure red cell aplasia in major ABO-mismatched allogeneic hematopoietic stem cell transplant with single agent Ibrutinib.. **2022**,	0
161	The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact.. **2022**,	
160	Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma.. **2022**, 1-9	
159	Landscape of TP53 Alterations in Chronic Lymphocytic Leukemia Data Mining Mutation Databases.. **2022**, 12, 808886	0
158	Landscape of NOTCH1 mutations and co-occurring biomarker alterations in chronic lymphocytic leukemia.. **2022**, 116, 106827	
157	Proteogenomics refines the molecular classification of chronic lymphocytic leukemia.	0
156	Campylobacter infection in 4 patients treated with ibrutinib.. **2022**, 1	0
155	Real-world management of targeted therapies in chronic lymphocytic leukemia.. **2022**, 10781552221090869	1
154	Do reduced numbers of plasmacytoid dendritic cells contribute to the aggressive clinical course of COVID-19 in chronic lymphocytic leukemia?. **2022**, e13153	1
153	Targeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin Lymphomas.. **2022**, 14,	0

152	Novel Bruton's Tyrosine Kinase (BTK) substrates for time-resolved luminescence assays.	
151	The Development of BTK Inhibitors: A Five-Year Update. **2021**, 26,	7
150	The TKI Era in Chronic Leukemias.. **2021**, 13,	2
149	Invasive Fungal Infections and Targeted Therapies in Hematological Malignancies.. **2021**, 7,	3
148	Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study.. **2021**, 14,	1
147	Understanding CLL biology through mouse models of human genetics.. **2021**, 138, 2621-2631	1
146	Infectious complications in patients with chronic lymphocytic leukemia treated with bruton's tyrosine kinase inhibitors. **2021**, 21, 15-27	
145	Breakage Study of the Urchinlike Crystal Clusters of Ibrutinib. **2022**, 26, 111-122	1
144	Targeted Treatment of Chronic Lymphocytic Leukemia: Clinical Utility of Acalabrutinib.. **2021**, 14, 5507-5519	0
143	A loss-of-adhesion CRISPR-Cas9 screening platform to identify cell adhesion-regulatory proteins and signaling pathways.. **2022**, 13, 2136	1
142	Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Future Directions.. **2022**, 11,	4
141	Ibrutinib Inhibits BMX-Dependent Endothelial VCAM-1 Expression In Vitro and Pro-Atherosclerotic Endothelial Activation and Platelet Adhesion In Vivo. 1	0
140	Cardiotoxicity of BTK inhibitors: ibrutinib and beyond.. **2022**,	2
139	The Ascension of Targeted Covalent Inhibitors.. **2022**,	3
138	Data_Sheet_1.docx. **2020**,	
137	Image_1.JPEG. **2020**,	
136	Image_2.JPEG. **2020**,	
135	Data_Sheet_1.PDF. **2018**,	

134	Table_1.DOC. **2018**,	
133	Table_2.DOC. **2018**,	
132	Table_3.DOC. **2018**,	
131	Table_4.DOC. **2018**,	
130	Table_5.docx. **2018**,	
129	Table_6.DOC. **2018**,	
128	Table_7.DOC. **2018**,	
127	Data_Sheet_1.docx. **2019**,	
126	Table_1.docx. **2020**,	
125	table_1.XLSX. **2018**,	
124	Characterization of metabolic alterations of Chronic Lymphocytic Leukemia in the lymph node microenvironment.. **2022**,	1
123	SOHO State of the Art Updates and Next Questions | Management of Most Difficult Cases of Chronic Lymphocytic Leukemia: Relapse After Both BTK and BCL2 Inhibition and Richter Transformation.. **2022**,	0
122	Modeling the B-cell receptor signaling on single cell level reveals a stable network circuit topology between non-malignant B cells and chronic lymphocytic leukemia cells and between untreated cells and cells treated with kinase inhibitors.. **2022**,	
121	B-cell Receptor Signaling Induced Metabolic Alterations in Chronic Lymphocytic Leukemia Can Be Partially Bypassed by TP53 Abnormalities. **2022**, 6, e722	0
120	Phenols in Pharmaceuticals: Analysis of a Recurring Motif.. **2022**,	7
119	BTK inhibitor selection for chronic lymphocytic leukemia: which drug for which patient?. **2022**,	0
118	Is there a real risk of bacterial infection in patients receiving targeted and biological therapies?. **2022**, 40, 266-272	
117	The Role of Inflammasomes in Osteoarthritis and Secondary Joint Degeneration Diseases. **2022**, 12, 731	0

116	In situ identification of cellular drug targets in mammalian tissue.. **2022**,	5
115	Cancers of the Blood. **2022**, 67-131	
114	Discovery of pyrrolo[1,2-a]quinoxalin-4(5H)-one Derivatives as Novel Non-covalent Bruton's Tyrosine Kinase (BTK) inhibitors. **2022**, 105860	
113	Reversible lysine-targeted probes reveal residence time-based kinase selectivity.. **2022**,	3
112	Kinase inhibitors: An overview. **2022**, 1-22	
111	Selinexor combined with ibrutinib demonstrates tolerability and safety in advanced B-cell malignancies: A phase I study.	0
110	Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia. **2022**, 12,	3
109	Medicinal Chemistry Strategies for the Development of Bruton's Tyrosine Kinase Inhibitors against Resistance.	1
108	Conformational, Toxic, Physicochemical and Molecular Docking Analysis of the Anticancer Acalabrutinib Molecule. **2022**, 7, 1-9	0
107	Zanubrutinib in lymphoproliferative disorders: a comprehensive review. **2022**, 13, 204062072210939	1
106	High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in CLL patients.	0
105	Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination. **2022**, 15,	0
104	T-helper cell regulation of CD45 phosphatase activity by galectin-1 and CD43 governs chronic lymphocytic leukaemia proliferation.	
103	Novel Bruton's Tyrosine Kinase (BTK) Substrates for Time-Resolved Luminescence Assays.	
102	Kinase-deficient BTK mutants confer ibrutinib resistance through activation of the kinase HCK. **2022**, 15,	0
101	Characterizing Features of Human Circulating B Cells Carrying CLL-Like Stereotyped Immunoglobulin Rearrangements. 12,	0
100	Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group. 1-14	0
99	Zanubrutinib for the Treatment of B-cell Malignancies. **2022**, 18, 44	

98	Efficacy and safety of ibrutinib in relapsed/refractory CLL and SLL in Japan: a post-marketing surveillance. **2022**,	
97	p66Shc Deficiency in Chronic Lymphocytic Leukemia Promotes Chemokine Receptor Expression Through the ROS-Dependent Inhibition of NF-B. 12,	0
96	Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib.	1
95	Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia. 12,	0
94	Integrin Signaling Shaping BTK-Inhibitor Resistance. **2022**, 11, 2235	
93	Leukemia-initiating HSCs in chronic lymphocytic leukemia reveal clonal leukemogenesis and differential drug sensitivity. **2022**, 40, 111115	
92	Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance. Volume 12, 81-98	0
91	Construction of lncRNA and mRNA co-expression network associated with nasopharyngeal carcinoma progression. 12,	
90	Enrichment of BTK Leu528Trp mutations in Patients with CLL on Zanubrutinib: Potential for Pirtobrutinib Cross Resistance.	2
89	A case report of pre-eclampsia-like endothelial injury in the kidney of an 85-year-old man treated with ibrutinib. **2022**, 23,	0
88	Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.	2
87	A phase I trial of BNC105P and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.	
86	Polymeric Carriers for Delivery of RNA Cancer Therapeutics. **2022**, 8, 58	1
85	Deep Learning-Based Label-Free Surface-Enhanced Raman Scattering Screening and Recognition of Small-Molecule Binding Sites in Proteins. **2022**, 94, 11483-11491	
84	A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression.	
83	Determining drug dose in the era of targeted therapies: playing it (un)safe?. **2022**, 12,	
82	Advances in covalent drug discovery.	9
81	Ibrutinib combined with low-dose histone deacetylases inhibitor chidamide synergistically enhances the anti-tumor effect in B-cell lymphoma.	

80	Progress in the Pathogenesis and Treatment of Neuropsychiatric Systemic Lupus Erythematosus. **2022**, 11, 4955	1
79	Platelets and tyrosine kinase inhibitors: clinical features, mechanism of action and effects on physiology.	0
78	Does the use of the Bruton Tyrosine Kinase inhibitors and the c-kit inhibitor masitinib result in clinically significant outcomes among patients with various forms of multiple sclerosis?. **2022**, 67, 104164	0
77	Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerations. **2022**, 13, 204062072211165	
76	B cell receptor (BCR) endocytosis. **2022**,	0
75	Estimation of Ibrutinib in Dosage Form and in Bulk Drug by UV Spectrophotometric and Colorimetry Methods. **2022**, 245-250	0
74	Quantitative evaluation and pharmacokinetic characteristics of the irreversible BTK inhibitor zanubrutinib in mouse plasma using LC-MS/MS. **2022**, 28, 81-88	0
73	Orelabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients: Multi-center, Single-arm, Open-label, Phase 2 Study.	0
72	Richter Syndrome: From Molecular Pathogenesis to Druggable Targets. **2022**, 14, 4644	1
71	The safety of Bruton's tyrosine kinase inhibitors in B-cell malignancies: A systematic review.	0
70	Perioperative Bleeding Associated With Ibrutinib in Dermatologic Surgery: A Case□Control Study. **2022**, Publish Ahead of Print,	0
69	Fibrillation atriale associˆ èˆ l'ibrutinib´ :´ un challenge thˆ rapeutique. **2022**,	0
68	Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner. **2022**, 14, 1876	0
67	BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies. **2022**, 15,	1
66	Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis. Volume 16, 3473-3490	0
65	Receptors of immune cells mediates recognition for tumors. **2022**,	0
64	Bruton□ Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis. **2022**, 11, 6139	1
63	Effect of antiplatelet agents and tyrosine kinase inhibitors on oxLDL-mediated procoagulant platelet activity.	0

62	Developing potent BTKC481S PROTACs for ibrutinib-resistant malignant lymphoma. **2022**, 107924	0
61	DOCK2 and phosphoinositide-3 kinase mediate two complementary signaling pathways for CXCR5-dependent B cell migration. 13,	0
60	Proteogenomics refines the molecular classification of chronic lymphocytic leukemia. **2022**, 13,	0
59	Pyrazoline Containing Compounds as Therapeutic Targets for Neurodegenerative Disorders. **2022**, 7, 38207-38245	0
58	Chronic Lymphocytic Leukemia. 1-11	0
57	Immunoglobulin replacement in hematological malignancies: a focus on evidence, alternatives, dosing strategy, and cessation rule. 1-12	0
56	GATA-3 is a proto-oncogene in T-cell lymphoproliferative neoplasms. **2022**, 12,	0
55	Selective Inhibition of Bruton's Tyrosine Kinase by a Designed Covalent Ligand Leads to Potent Therapeutic Efficacy in Blood Cancers Relative to Clinically Used Inhibitors.	0
54	A systematic review of contemporary phase I trials in patients with lymphoma. **2022**, 180, 103860	0
53	Renal adverse reactions of tyrosine kinase inhibitors in the treatment of tumours: A Bayesian network meta-analysis. 13,	0
52	VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia.	0
51	BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK´ inhibitor in BTK´ inhibitor´ naˆ ve mantle cell lymphoma.	1
50	Recurrent Optic Neuritis and Perineuritis Followed by an Unexpected Discovery. **2023**, 10, e200051	0
49	Evaluating orelabrutinib as a novel treatment option for relapsed/refractory chronic lymphocytic leukemia in China. 1-8	1
48	Advances in Understanding of Metabolism of B-Cell Lymphoma: Implications for Therapy. **2022**, 14, 5552	0
47	Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study. **2022**,	2
46	Richter transformation to aggressive plasmablastic neoplasm related to selection of a BTK-mutated clone in a patient with CLL/SLL treated by ibrutinib. 1-4	0
45	How Have Targeted Agents Changed the Treatment Landscape for Elderly Patients with CLL?.	0

44	Old and New Facts and Speculations on the Role of the B Cell Receptor in the Origin of Chronic Lymphocytic Leukemia. **2022**, 23, 14249	1
43	Co-delivery of ibrutinib and hydroxychloroquine by albumin nanoparticles for enhanced chemotherapy of glioma. **2023**, 630, 122436	1
42	Hide and Seek: The Game Between Chronic Lymphocytic Leukaemia Cells and B Cell Receptor Signalling Inhibitors. 24-30	0
41	Intraocular Lymphoma. **2022**,	0
40	Richter transformation in Chronic Lymphocytic Leukemia.	0
39	SHP1 loss augments DLBCL cellular response to ibrutinib: a candidate predictive biomarker.	0
38	Novel targeted treatments in hairy cell leukemia and other hairy cell-like disorders. 12,	0
37	Small molecules in the treatment of COVID-19. **2022**, 7,	3
36	CNS-invasive aspergillosis following ibrutinib therapy. **2022**, 8, 001-003	0
35	A phase 1, open-label, randomized drug□drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies. 1-10	0
34	Therapeutic effect of ibrutinib, a selective Bruton□s tyrosine kinase inhibitor, in orbital fibroblasts from patients with Graves□ orbitopathy. **2022**, 17, e0279060	0
33	Orelabrutinib and venetoclax synergistically induce cell death in double-hit lymphoma by interfering with the crosstalk between the PI3K/AKT and p38/MAPK signaling.	0
32	Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.	7
31	Making modern medicines For Blood and Money; Billionaires, Biotech, and the Quest for a Blockbuster Drug Nathan Vardi Norton, 2023. 288 pp.. **2022**, 378, 1283-1283	0
30	Genetics and epigenetics of CLL. 1-13	0
29	Discovery of structural diverse reversible BTK inhibitors utilized to develop a novel in vivo CD69 and CD86 PK/PD mouse model. **2022**, 129108	0
28	Cardiovascular Toxicities of Ibrutinib: A Pharmacovigilance Study Based on the United States Food and Drug Administration Adverse Event Reporting System Database. **2023**, 16, 98	1
27	Oral azole antifungal prophylaxis in Japanese patients with chronic lymphocytic leukemia receiving ibrutinib: a nationwide cohort study. 1-4	0

26	Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies.	0
25	Review of the Efficacy of Bruton Tyrosine Kinase (BTK) Inhibitors on Primary Central Nervous System Lymphoma. **2023**, 13, 1083-1091	0
24	Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study.	1
23	Ibrutinib in relapsed/refractory patients with Waldenstr ˆ n macroglobulinemia: a real-life, retrospective study on behalf of the R TL (regional Tuscan lymphoma network).	0
22	Recent revelations and future directions using single-cell technologies in chronic lymphocytic leukemia. 13,	0
21	A History of Targeted Therapy Development and Progress in Novel Novel Combinations for Chronic Lymphocytic Leukemia (CLL). **2023**, 15, 1018	0
20	2-Ethynylbenzaldehyde-Based, Lysine-Targeting Irreversible Covalent Inhibitors for Protein Kinases and Nonkinases.	0
19	Controlling Ibrutinib Conformations about Its Heterobiaryl Axis to Increase BTK Selectivity. **2023**, 14, 305-311	0
18	Measurable residual disease in chronic lymphocytic leukemia. 13,	0
17	A mechanistic study of thiol addition to N-acryloylpiperidine. **2023**, 21, 2204-2212	0
16	Exploring the Incorporation of a Novel Cardiotoxicity Mobile Health App into Cancer Patient Care: Patient and Provider Perspectives (Preprint).	0
15	The evolving use of measurable residual disease in chronic lymphocytic leukemia clinical trials. 13,	0
14	Recurrent Cellulitis Revealing Helicobacter cinaedi in Patient on Ibrutinib Therapy, France. **2023**, 29, 640-641	0
13	Current Landscape of Ancillary Diagnostic Testing in Chronic Lymphocytic Leukemia. **2023**,	0
12	Real-world outcomes upon second-line treatment in patients with chronic lymphocytic leukaemia.	0
11	Targeted engagement of -catenin-Ikaros complexes in refractory B-cell malignancies.	0
10	Precision diagnostics in chronic lymphocytic leukemia: Past, present and future. 13,	0
9	Health disparity in use of novel agents for first-line therapy in Black and White patients with chronic lymphocytic leukemia in the Department of Veterans Affairs. **2023**, 29, 420-430	0

8	The cat-and-mouse game of BTK inhibition. **2023**, 141, 1502-1503	0
7	Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity.	0
6	Bruton's Tyrosine Kinase inhibition by Acalabrutinib does not affect early or advanced atherosclerotic plaque size and morphology in Ldlr mice. **2023**, 150, 107172	0
5	How We Manage Patients with Indolent B-Cell Malignancies on Bruton Tyrosine Kinase Inhibitors: Practical Considerations for Nurses and Pharmacists. **2023**, 30, 4222-4245	0
4	Ibrutinib Is Associated With Increased Cardiovascular Events and Major Bleeding in Older CLL Patients. **2023**, 5, 233-243	0
3	Fatal Cryptococcal Meningitis in a Patient With Chronic Lymphocytic Leukemia Treated With Ibrutinib. **2023**,	0
2	Targeted therapy. **2023**, 205-411	0
1	Population-level impact of ibrutinib for chronic lymphocytic leukemia in British Columbia, Canada. 1-10	0